[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 204
1. Sarkar IN, Egan MG, Coruzzi G, Lee EK, DeSalle R: Automated simultaneous analysis phylogenetics (ASAP): an enabling tool for phlyogenomics. BMC Bioinformatics; 2008;9:103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated simultaneous analysis phylogenetics (ASAP): an enabling tool for phlyogenomics.
  • A significant bottleneck in the analysis of genomic-scale views of the tree of life is the time required for manual curation of genomic data into multi-gene phylogenetic matrices.
  • RESULTS: To keep pace with the exponentially growing volume of molecular data in the genomic era, we have developed an automated technique, ASAP (Automated Simultaneous Analysis Phylogenetics), to assemble these multigene/multi species matrices and to evaluate the significance of individual genes within the context of a given phylogenetic hypothesis.
  • CONCLUSION: Applications of ASAP may enable scientists to re-evaluate species relationships and to develop new phylogenomic hypotheses based on genome-scale data.
  • [MeSH-major] Algorithms. Chromosome Mapping / methods. Evolution, Molecular. Phylogeny. Sequence Alignment / methods. Sequence Analysis, DNA / methods. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Syst Biol. 1999 Mar;48(1):6-20 [12078645.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):193-8 [12717435.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):798-804 [14574403.001]
  • [Cites] Syst Biol. 2007 Apr;56(2):355-63 [17464890.001]
  • [Cites] Bioinformatics. 2005 Dec 15;21(24):4423-4 [16267088.001]
  • [Cites] Bioinformatics. 2006 Mar 15;22(6):699-707 [16410324.001]
  • [Cites] BMC Evol Biol. 2006;6:48 [16776834.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):1792-7 [15034147.001]
  • (PMID = 18282301.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2270260
  •  go-up   go-down


2. Eot-Houllier G, Venoux M, Vidal-Eychenié S, Hoang MT, Giorgi D, Rouquier S: Plk1 regulates both ASAP localization and its role in spindle pole integrity. J Biol Chem; 2010 Sep 17;285(38):29556-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plk1 regulates both ASAP localization and its role in spindle pole integrity.
  • ASAP (aster-associated protein or MAP9) is a centrosome- and spindle-associated protein, the deregulation of which induces severe mitotic defects.
  • Here, we show that ASAP is localized to the spindle poles by Polo-like kinase 1 (Plk1) (a mitotic kinase that plays an essential role in centrosome regulation and mitotic spindle assembly) through the γ-TuRC-dependent pathway.
  • We also demonstrate that ASAP is a novel substrate of Plk1 phosphorylation and have identified serine 289 as the major phosphorylation site by Plk1 in vivo.
  • ASAP phosphorylated on serine 289 is localized to centrosomes during mitosis, but this phosphorylation is not required for its Plk1-dependent localization at the spindle poles.
  • We show that phosphorylated ASAP on serine 289 contributes to spindle pole stability in a microtubule-dependent manner.
  • These data reveal a novel function of ASAP in centrosome integrity.
  • Our results highlight dual ASAP regulation by Plk1 and further confirm the importance of ASAP for spindle pole organization, bipolar spindle assembly, and mitosis.

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2006 Apr;5(8):853-64 [16627997.001]
  • [Cites] J Cell Biol. 2006 Feb 13;172(4):505-15 [16461362.001]
  • [Cites] J Cell Sci. 2006 Oct 15;119(Pt 20):4143-53 [17038541.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2717-23 [17016823.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63 [17505520.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5362-70 [17545617.001]
  • [Cites] Mol Biol Cell. 2007 Oct;18(10):4024-36 [17671160.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):911-24 [18004399.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):215-24 [17925329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1442-7 [18234856.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):331-41 [18331714.001]
  • [Cites] Dev Cell. 2008 May;14(5):646-59 [18477449.001]
  • [Cites] Science. 2008 Jun 20;320(5883):1655-8 [18566290.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):119-23 [18615013.001]
  • [Cites] Chromosoma. 2008 Oct;117(5):457-69 [18521620.001]
  • [Cites] Genes Dev. 2008 Oct 1;22(19):2707-20 [18832073.001]
  • [Cites] J Cell Biol. 2008 Dec 1;183(5):835-48 [19029337.001]
  • [Cites] Biol Cell. 2009 Jan;101(1):1-11 [19055485.001]
  • [Cites] Oncogene. 2009 Jan 8;28(1):107-16 [18820703.001]
  • [Cites] J Cell Sci. 2009 May 1;122(Pt 9):1334-41 [19351716.001]
  • [Cites] Curr Biol. 2009 May 26;19(10):816-26 [19427217.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4555-8 [19487276.001]
  • [Cites] J Cell Sci. 2009 Jul 1;122(Pt 13):2240-51 [19509060.001]
  • [Cites] PLoS One. 2009;4(6):e5976 [19543530.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87 [19546858.001]
  • [Cites] Trends Cell Biol. 2009 Jul;19(7):334-46 [19570677.001]
  • [Cites] EMBO J. 2009 Jul 22;28(14):2066-76 [19536135.001]
  • [Cites] J Cell Sci. 2009 Aug 1;122(Pt 15):2750-9 [19596795.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2413-9 [19556869.001]
  • [Cites] EMBO J. 2009 Sep 16;28(18):2786-93 [19680222.001]
  • [Cites] Cell Mol Life Sci. 2010 Jun;67(12):1957-70 [20148280.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):672-6 [10980711.001]
  • [Cites] J Cell Biol. 2001 Apr 2;153(1):149-58 [11285281.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6209-21 [12167714.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Science. 2003 Feb 21;299(5610):1228-31 [12595692.001]
  • [Cites] Cell. 2003 Oct 3;115(1):83-95 [14532005.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40 [15173822.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36841-54 [15210710.001]
  • [Cites] Curr Biol. 2004 Oct 5;14(19):1712-22 [15458642.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Oncogene. 2005 Jan 10;24(2):248-59 [15640840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11302-7 [16049101.001]
  • [Cites] Mol Biol Cell. 2006 Jan;17(1):448-59 [16267267.001]
  • [Cites] Nat Cell Biol. 2006 Feb;8(2):137-47 [16378099.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1095-101 [16980960.001]
  • (PMID = 20615875.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 0 / NEDD1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Tubulin; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ PMC2937987
  •  go-up   go-down


3. Glasner JD, Rusch M, Liss P, Plunkett G 3rd, Cabot EL, Darling A, Anderson BD, Infield-Harm P, Gilson MC, Perna NT: ASAP: a resource for annotating, curating, comparing, and disseminating genomic data. Nucleic Acids Res; 2006 Jan 1;34(Database issue):D41-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASAP: a resource for annotating, curating, comparing, and disseminating genomic data.
  • ASAP is a comprehensive web-based system for community genome annotation and analysis.
  • ASAP is being used for a large-scale effort to augment and curate annotations for genomes of enterobacterial pathogens and for additional genome sequences.
  • New tools, such as the genome alignment program Mauve, have been incorporated into ASAP in order to improve display and analysis of related genomes.
  • ASAP is available on the web at https://asap.ahabs.wisc.edu/asap/logon.php.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brief Bioinform. 2003 Jun;4(2):124-32 [12846394.001]
  • [Cites] Bioinformatics. 2005 Sep 15;21(18):3669-71 [16076887.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D296-9 [14681417.001]
  • [Cites] Genome Biol. 2004;5(2):R12 [14759262.001]
  • [Cites] Infect Immun. 2004 Jul;72(7):4114-26 [15213157.001]
  • [Cites] Genome Res. 2004 Jul;14(7):1394-403 [15231754.001]
  • [Cites] Mol Plant Microbe Interact. 2004 Sep;17(9):999-1008 [15384490.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Microb Comp Genomics. 2000;5(4):205-22 [11471834.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):147-51 [12519969.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):617-23 [15501914.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W116-20 [15980438.001]
  • [Cites] Bioinformatics. 2005 Aug 15;21(16):3422-3 [15976072.001]
  • [Cites] Genome Biol. 2005;6(8):229 [16086859.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61 [14681407.001]
  • (PMID = 16381899.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1347526
  •  go-up   go-down


Advertisement
4. Saffin JM, Venoux M, Prigent C, Espeut J, Poulat F, Giorgi D, Abrieu A, Rouquier S: ASAP, a human microtubule-associated protein required for bipolar spindle assembly and cytokinesis. Proc Natl Acad Sci U S A; 2005 Aug 9;102(32):11302-7
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASAP, a human microtubule-associated protein required for bipolar spindle assembly and cytokinesis.
  • We have identified a unique human microtubule-associated protein (MAP) named ASAP for ASter-Associated Protein.
  • ASAP localizes to microtubules in interphase, associates with the mitotic spindle during mitosis, localizes to the central body during cytokinesis and directly binds to purified microtubules by its COOH-terminal domain.
  • Overexpression of ASAP induces profound bundling of cytoplasmic microtubules in interphase cells and aberrant monopolar spindles in mitosis.
  • Depletion of ASAP by RNA interference results in severe mitotic defects: it provokes aberrant mitotic spindle, delays mitotic progression, and leads to defective cytokinesis or cell death.
  • These results suggest a crucial role for ASAP in the organization of the bipolar mitotic spindle, mitosis progression, and cytokinesis and define ASAP as a key factor for proper spindle assembly.
  • [MeSH-minor] Base Sequence. Blotting, Western. Cells, Cultured. Cloning, Molecular. Glutathione Transferase. Humans. Microscopy, Fluorescence. Molecular Sequence Data. Oligonucleotides. RNA Interference. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Oct 19;294(5542):543-7 [11641489.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):E28-34 [11146647.001]
  • [Cites] J Cell Biol. 2002 Nov 25;159(4):549-55 [12438418.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2876-89 [12857871.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):773-6 [12951607.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40 [15173822.001]
  • [Cites] J Cell Biol. 2004 Jun 21;165(6):813-22 [15197175.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):179-91 [15249581.001]
  • [Cites] J Cell Biol. 1990 Nov;111(5 Pt 1):1905-11 [2229180.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):7143-51 [8524282.001]
  • [Cites] Scanning Microsc. 1995 Sep;9(3):843-57; discussion 858-60 [7501997.001]
  • [Cites] J Cell Biol. 1998 Mar 9;140(5):991-1002 [9490714.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;39(3):223-32 [9519903.001]
  • [Cites] Trends Biochem Sci. 1998 Aug;23(8):307-11 [9757832.001]
  • [Cites] Chromosoma. 1998 Dec;107(6-7):461-70 [9914378.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):637-51 [15525526.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Science. 1999 Oct 29;286(5441):971-4 [10542155.001]
  • [Cites] EMBO J. 1999 Dec 1;18(23):6786-92 [10581251.001]
  • [Cites] Trends Cell Biol. 2000 Jun;10(6):228-37 [10802538.001]
  • [Cites] Annu Rev Biochem. 2000;69:95-114 [10966454.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):767-75 [11056530.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5711-9 [11060022.001]
  • [Cites] J Cell Biol. 2000 Dec 25;151(7):1575-82 [11134084.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1175-86 [12082078.001]
  • (PMID = 16049101.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY690636
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 0 / Oligonucleotides; EC 2.5.1.18 / Glutathione Transferase
  • [Other-IDs] NLM/ PMC1183541
  •  go-up   go-down


5. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D: Atypical small acinar proliferation: biopsy artefact or distinct pathological entity? BJU Int; 2007 Apr;99(4):780-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
  • OBJECTIVE: To determine if atypical small acinar proliferation (ASAP) represents minimally sampled prostate cancer not fully evaluated on a biopsy or a distinct pathological entity, by examining prostates removed at radical cystectomy, as a finding of ASAP of the prostate on needle-core biopsy is closely associated with the detection of cancer on subsequent biopsy.
  • PATIENTS AND METHODS: In all, 65 consecutive cystoprostatectomy specimens taken from June 1990 to March 2004 had prostatic material reviewed by one genitourinary pathologist (S.E.M.).
  • The presence of high-grade prostatic intraepithelial neoplasia (HGPIN), ASAP, and adenocarcinoma was recorded.
  • Foci of ASAP found in the absence of cancer were assessed with additional sectioning, high-molecular weight keratin (CK903), and alpha-methylacyl coenzyme A racemase (AMACR) immunohistochemistry.
  • Of the 41 without cancer, 18 (44%) had neither HGPIN nor ASAP, 14 (34%) had HGPIN alone, three (7%) had ASAP alone (four foci), and six had both HGPIN and ASAP (15%).
  • Two foci of ASAP were not present on any further sectioning.
  • CONCLUSION: ASAP identified in incidental prostates represented marginally sampled cancer in at least two of 10 foci assessed.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Cystectomy / methods. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Prostate / pathology. Prostatectomy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378841.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Kuroda N, Katto K, Tamura M, Shiotsu T, Nakamura S, Ohtsuki Y, Hes O, Michal M, Inoue K, Ohara M, Mizuno K, Lee GH: Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials. Med Mol Morphol; 2010 Sep;43(3):165-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials.
  • D2-40 has been recently discovered as a lymphatic endothelial cell marker, and some investigators have found that D2-40 is also expressed in myoepithelial cells of salivary gland or breast.
  • In this study, we evaluated D2-40 expression of basal cells and applied D2-40 immunohistochemistry in the combination of P504S, cytokeratin 5, and p63 for ten lesions with atypical small acinar proliferation (ASAP) in initial prostatic needle biopsy.
  • As a result, D2-40 was expressed in basal cells, lymphatic endothelial cells, and some stromal fibroblasts of normal prostatic tissue.
  • Among ten ASAP lesions, the final diagnosis of seven lesions was resolved by combination immunohistochemistry.
  • However, we found some D2-40-positive stromal fibroblasts or D2-40-positive lumen-collapsed lymphatic vessels neighboring atypical glands.
  • In conclusion, the combination of immunohistochemistry of P504S, cytokeratin 5, p63, and D2-40 may contribute to the accurate diagnosis of ASAP in the initial prostatic needle biopsy.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biopsy, Needle. Early Diagnosis. Humans. Immunohistochemistry. Keratin-5 / isolation & purification. Male. Membrane Proteins / isolation & purification. Middle Aged. Prostate / pathology. Racemases and Epimerases / isolation & purification. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):946-52 [15223967.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] BJU Int. 2001 Jan;87(1):70-4 [11201402.001]
  • [Cites] Ann Diagn Pathol. 2006 Aug;10(4):205-8 [16844561.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):925-31 [10435562.001]
  • [Cites] Med Mol Morphol. 2008 Jun;41(2):109-12 [18592165.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):1011-6 [16757205.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):557-60 [15086303.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1435-41 [16224209.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):287-90 [16341144.001]
  • [Cites] Histopathology. 2007 Nov;51(5):719-21 [17927601.001]
  • [Cites] BJU Int. 2007 Jan;99(1):49-52 [17227491.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1430-1 [9808137.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):175-83 [18206495.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1180-90 [15205683.001]
  • [Cites] J Urol. 2001 Sep;166(3):866-70 [11490235.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Am J Clin Pathol. 2000 Dec;114(6):896-909 [11338479.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • (PMID = 20857265.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins; 0 / monoclonal antibody D2-40; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


7. Shi HY, Wei LX, Zhou ZH, Wen ZL: [Morphologic diagnosis and clinical significance of prostatic atypical small acinar proliferation suspicious but not diagnostic of cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):660-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic diagnosis and clinical significance of prostatic atypical small acinar proliferation suspicious but not diagnostic of cancer].
  • OBJECTIVE: To study the morphologic features and clinical significance of atypical small acinar proliferation (ASAP) suspicious but not diagnostic of cancer in prostatic biopsies.
  • METHODS: The slides of 11 cases of prostatic needle biopsies collected during a two-year period with the diagnosis of ASAP were reviewed.
  • RESULTS: All the 11 ASAP cases were characterized by the presence of a few compacted small acini in the prostatic stroma.
  • The nuclei were slightly enlarged with small or inconspicuous nucleoli.
  • CONCLUSIONS: ASAP is a morphologic interpretation closely associated with prostatic adenocarcinoma.
  • The histologic features are suspicious of but not diagnostic of cancer, due to insufficient criteria in terms of acinar number, cytologic or architectural abnormalities.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374209.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


8. Bostwick DG, Meiers I: Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med; 2006 Jul;130(7):952-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation in the prostate: clinical significance in 2006.
  • About 2% of contemporary prostate needle biopsy specimens contain collections of small acini that are suspicious for cancer but that fall below the diagnostic threshold and are reported as atypical small acinar proliferation suspicious for but not diagnostic of malignancy.
  • Prostate cancer has been identified in specimens from subsequent biopsies in up to 60% of cases of atypical small acinar proliferation, indicating that this finding is a significant predictor of cancer.
  • Identification of atypical small acinar proliferation warrants repeat biopsy for concurrent or subsequent invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Cell Proliferation. Diagnosis, Differential. Follow-Up Studies. Humans. Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831049.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


9. Greenstein M, Ben Ishay R, Maoz BM, Leader H, Vaskevich A, Rubinstein I: Rapid formation of coordination multilayers using accelerated self-assembly procedure (ASAP). Langmuir; 2010 May 18;26(10):7277-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid formation of coordination multilayers using accelerated self-assembly procedure (ASAP).
  • Here we describe a method for LbL synthesis of self-assembled coordination multilayers denoted accelerated self-assembly procedure (ASAP), where binding of a full organic ligand layer occurs in ca. 1 min.
  • In the new protocol a small volume of a dilute ligand solution is spread on the substrate surface and evaporated under natural convection conditions, leaving the surface covered with excess ligand.
  • ASAP is demonstrated here by the construction of two kinds of coordination multilayers, comprising mercaptoundecanoic acid-Cu(II) and bishydroxamate-Zr(IV).
  • Multilayers prepared by ASAP and by the standard (overnight adsorption) procedure are compared using ellipsometry, contact-angle, and FTIR data, showing regular multilayer growth in both cases.
  • However, the rapid binding associated with ASAP may lead to a different structure than the one reached after prolonged assembly.
  • Study of the ASAP mechanism suggests that the fast ligand binding kinetics are attributed to a large increase of the local ligand concentration at the moving liquid front when the solvent evaporates on the surface.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163094.001).
  • [ISSN] 1520-5827
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ray AD, Hammond J, Major H: Molecular ions and protonated molecules observed in the atmospheric solids analysis probe analysis of steroids. Eur J Mass Spectrom (Chichester); 2010;16(2):169-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular ions and protonated molecules observed in the atmospheric solids analysis probe analysis of steroids.
  • Atmospheric pressure chemical ionisation (APCI) has often been used to ionise steroids in mass spectrometry, usually when interfaced to high-performance liquid chromatography (HPLC).
  • The recently introduced technique of atmospheric solids analysis probe (ASAP) has the advantage that the sample can be analysed directly and does not need to be interfaced to HPLC.
  • Existing ionisation sources such as direct analysis in real time (DART) and desorption electrospray ionisation (DESI) have shown the advantage of direct analysis techniques in a variety of applications.
  • ASAP can be performed on commercial atmospheric pressure ionisation (API) mass spectrometers with only simple modifications to API sources.
  • A range of commercially available steroids were analysed by ASAP to investigate the mechanism of ionisation.
  • ASAP analysis of steroids generally results in the formation of the parent molecular ion as either the radical cation M+* or the protonated molecule MH+.
  • [MeSH-major] Atmospheric Pressure. Protons. Spectrometry, Mass, Electrospray Ionization / methods. Steroids / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212333.001).
  • [ISSN] 1469-0667
  • [Journal-full-title] European journal of mass spectrometry (Chichester, England)
  • [ISO-abbreviation] Eur J Mass Spectrom (Chichester)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protons; 0 / Steroids
  •  go-up   go-down


11. Drewnowska K, Crawford ED, Qian J, Varvel S, Wilk M, Mason L, Kaminetsky J, Huisman TK, Bilowus M, Freedman SJ, Bostwick DG: PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA. J Clin Oncol; 2009 May 20;27(15_suppl):5054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA.
  • : 5054 Background: Currently, early detection of prostate cancer relies primarily on an abnormal digital rectal examination (DRE) and an elevated prostate-specific antigen (PSA) level leading to a prostate biopsy.
  • We investigated the value of a new molecular marker-PCA3 in predicting the likelihood of prostate cancer.
  • Urine samples were obtained from 974 men with elevated serum PSA (> 2.5ng/ml) and/or abnormal digital rectal examination prior to routine minimum 10-core prostate biopsy following standard study protocol in 30 medical practices.
  • RESULTS: In total, 380 of 974 patients (39%) were diagnosed with prostate cancer, with a mean Gleason score of 7 (range, 6-9) and 26% (range 1-100%) of the biopsy specimens involved by cancer.
  • An additional 106 cases (11%) had only high-grade PIN and/or atypical small acinar proliferation suspicious for cancer (ASAP), and 488 cases (50%) were benign.
  • The mean PCA3 value in men with prostate cancer was significantly higher than in those without cancer (48 vs. 26, p < 0.0001).
  • Using a cutoff value of 35, PCA3 had an odds ratio of 2.6 for predicting prostate cancer.
  • PCA3 had a specificity of 77% and a sensitivity of 44% for the diagnosis of prostate cancer, while the specificity and sensitivity for serum PSA were 22% and 87%, respectively.
  • CONCLUSIONS: We found that the PCA3 urine test significantly improved the specificity for the detection of prostate cancer compared to serum PSA.
  • Further evaluation of this urinary marker in screening for prostate cancer appears indicated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. López JI: Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation. BJU Int; 2007 Dec;100(6):1272-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation.
  • OBJECTIVE: To review specific histological variables in patients with prostate cancer who previously had diagnoses of high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP), compared with those who had no such diagnoses.
  • PATIENTS AND METHODS: The histological characteristics of prostate cancers which were detected after a previous diagnosis of HGPIN and/or ASAP during 1998-2005 were investigated and correlated with the biopsies from patients with prostate cancer but with no such previous diagnoses.
  • RESULTS: HGPIN was followed by prostate cancer on repeat biopsy in 16.8% of patients, and ASAP in 26.7%.
  • The mean age of patients with HGPIN or ASAP was higher than in those with no such diagnoses (P < 0.001).
  • CONCLUSIONS: Patients with prostate cancer who had previous biopsies with HGPIN or ASAP were older and has lower grade- and volume-cancers than those who had not.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Humans. Immunohistochemistry. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850386.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Venoux M, Delmouly K, Milhavet O, Vidal-Eychenié S, Giorgi D, Rouquier S: Gene organization, evolution and expression of the microtubule-associated protein ASAP (MAP9). BMC Genomics; 2008;9:406
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene organization, evolution and expression of the microtubule-associated protein ASAP (MAP9).
  • BACKGROUND: ASAP is a newly characterized microtubule-associated protein (MAP) essential for proper cell-cycling.
  • We have previously shown that expression deregulation of human ASAP results in profound defects in mitotic spindle formation and mitotic progression leading to aneuploidy, cytokinesis defects and/or cell death.
  • In the present work we analyze the structure and evolution of the ASAP gene, as well as the domain composition of the encoded protein.
  • RESULTS: Bona fide ASAP orthologs are found in vertebrates with more distantly related potential orthologs in invertebrates.
  • ASAP is composed of approximately 42% alpha helical structures, and two main coiled-coil regions have been identified.
  • As with human ASAP, the mouse and Xenopus proteins localize to the microtubule network in interphase and to the mitotic spindle during mitosis.
  • In situ hybridization in testis localized ASAP to the germ cells, whereas in culture neurons ASAP localized to the cell body and growing neurites.
  • CONCLUSION: The conservation of ASAP indicated in our results reflects an essential function in vertebrates.
  • We have cloned the ASAP orthologs in mouse and Xenopus, two valuable models to study the function of ASAP.
  • Tissue expression of ASAP revealed a high expression in brain and testis, two tissues rich in microtubules.
  • ASAP associates to the mitotic spindle and cytoplasmic microtubules, and represents a key factor of mitosis with possible involvement in other cell cycle processes.
  • Possible involvement in neuron dynamics also highlights ASAP as a candidate target in neurodegenerative diseases.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1332-42 [10837026.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Aug;46(4):235-46 [10962478.001]
  • [Cites] Annu Rev Biochem. 2000;69:95-114 [10966454.001]
  • [Cites] Annu Rev Biochem. 2000;69:277-302 [10966460.001]
  • [Cites] Nat Rev Neurosci. 2007 May;8(5):368-78 [17453017.001]
  • [Cites] Science. 2007 May 25;316(5828):1160-6 [17525332.001]
  • [Cites] Cell Mol Life Sci. 2007 Aug;64(15):1891-914 [17483873.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):215-24 [17925329.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):E28-34 [11146647.001]
  • [Cites] Science. 2001 Oct 19;294(5542):543-7 [11641489.001]
  • [Cites] Hum Mol Genet. 2001 Nov 15;10(24):2813-20 [11734546.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):153-63 [11809724.001]
  • [Cites] Trends Cell Biol. 2002 Jan;12(1):21-7 [11854006.001]
  • [Cites] Trends Cell Biol. 2002 Jun;12(6):267-73 [12074886.001]
  • [Cites] Nature. 2000 Sep 7;407(6800):41-7 [10993066.001]
  • [Cites] Nature. 1984 Nov 15-21;312(5991):237-42 [6504138.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Cell Motil Cytoskeleton. 1988;10(1-2):185-96 [3180243.001]
  • [Cites] J Cell Biol. 1989 Dec;109(6 Pt 2):3367-76 [2480963.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] J Biol Chem. 1991 May 25;266(15):9841-6 [2033072.001]
  • [Cites] J Cell Sci. 1991 Jan;98 ( Pt 1):27-36 [1905296.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):21886-96 [1718985.001]
  • [Cites] Biol Reprod. 1992 Jan;46(1):120-9 [1547309.001]
  • [Cites] J Cell Biol. 1993 Feb;120(4):935-45 [8432733.001]
  • [Cites] Nature. 1993 Aug 19;364(6439):717-21 [8355785.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):661-72 [8006079.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Biol Reprod. 1996 Apr;54(4):896-904 [8924511.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):420-5 [8684481.001]
  • [Cites] J Cell Biol. 1997 Sep 8;138(5):953-6 [9281574.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:83-117 [9442869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5857-64 [9600884.001]
  • [Cites] Exp Cell Res. 1998 Jul 10;242(1):60-8 [9665802.001]
  • [Cites] J Cell Sci. 1998 Nov;111 ( Pt 21):3167-77 [9763511.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6653-65 [9774680.001]
  • [Cites] Curr Opin Struct Biol. 1998 Dec;8(6):785-91 [9914260.001]
  • [Cites] Neuron. 1999 Jan;22(1):23-31 [10027286.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):134-41 [10047516.001]
  • [Cites] Bioinformatics. 1999 May;15(5):413-21 [10366661.001]
  • [Cites] J Cell Biol. 1999 Sep 20;146(6):1205-10 [10491385.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2155-65 [15972725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11302-7 [16049101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13813-8 [16174732.001]
  • [Cites] Hum Mol Genet. 2005 Nov 1;14(21):3113-28 [16203747.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R291-300 [16244328.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D257-60 [16381859.001]
  • [Cites] Stem Cells. 2006 Oct;24(10):2284-91 [16741225.001]
  • [Cites] Biochim Biophys Acta. 2007 Apr;1772(4):457-66 [17158035.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):E177-84 [12105431.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):347-8 [12134148.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:193-219 [12142285.001]
  • [Cites] Development. 2003 May;130(9):1783-94 [12642484.001]
  • [Cites] Genomics. 2003 Apr;81(4):437-41 [12676568.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):753-8 [12700769.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):505-11 [12776127.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Aug;62(8):878-82 [14503643.001]
  • [Cites] Neuromolecular Med. 2003;4(1-2):37-48 [14528051.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):426-7 [14960472.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):71-6 [15147871.001]
  • [Cites] Clin Genet. 2004 Oct;66(4):341-8 [15355437.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Cell Biol. 2004 Sep 27;166(7):949-55 [15452138.001]
  • [Cites] J Cell Biol. 1984 Dec;99(6):2287-96 [6501426.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):296-303 [10610178.001]
  • [Cites] Trends Biochem Sci. 2000 Mar;25(3):147-50 [10694887.001]
  • [Cites] Genome Res. 2000 Apr;10(4):577-86 [10779500.001]
  • [Cites] Trends Genet. 2000 Jun;16(6):276-7 [10827456.001]
  • (PMID = 18782428.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ASAP protein, Xenopus; 0 / DNA, Complementary; 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 0 / Mtap9 protein, mouse; 0 / Xenopus Proteins
  • [Other-IDs] NLM/ PMC2551623
  •  go-up   go-down


14. McEwen C, Gutteridge S: Analysis of the inhibition of the ergosterol pathway in fungi using the atmospheric solids analysis probe (ASAP) method. J Am Soc Mass Spectrom; 2007 Jul;18(7):1274-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the inhibition of the ergosterol pathway in fungi using the atmospheric solids analysis probe (ASAP) method.
  • Fungal cells treated with various inhibitors to the ergosterol pathway were analyzed using an Orbitrap mass spectrometer equipped with an atmospheric solids analysis probe (ASAP).
  • Furthermore, in an inhibitor concentration study, the ASAP method was able to rapidly provide an estimate of the effectiveness of inhibition.
  • In this method the cells are inserted directly into a hot nitrogen stream, thus eliminating extensive sample workup before analysis.
  • [MeSH-minor] Atmospheric Pressure. Transducers

  • Hazardous Substances Data Bank. ERGOSTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2005 Nov 1;77(21):6755-64 [16255571.001]
  • [Cites] Chem Commun (Camb). 2007 Feb 28;(8):807-9 [17308638.001]
  • [Cites] Anal Chem. 2005 Apr 15;77(8):2297-302 [15828760.001]
  • [Cites] Science. 2004 Oct 15;306(5695):471-3 [15486296.001]
  • [Cites] Chem Commun (Camb). 2005 Apr 21;(15):1950-2 [15834468.001]
  • [Cites] Anal Chem. 2005 Dec 1;77(23):7826-31 [16316194.001]
  • [Cites] Eur J Mass Spectrom (Chichester). 2004;10(2):197-204 [15103096.001]
  • [Cites] Bioorg Med Chem. 2000 May;8(5):925-36 [10882005.001]
  • [Cites] J Am Soc Mass Spectrom. 2005 Nov;16(11):1730-8 [16185892.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5389-95 [11087490.001]
  • [Cites] Anal Chem. 2001 Nov 1;73(21):5061-5 [11721900.001]
  • [Cites] Chem Commun (Camb). 2007 Jan 7;(1):61-3 [17279261.001]
  • (PMID = 17482834.001).
  • [ISSN] 1044-0305
  • [Journal-full-title] Journal of the American Society for Mass Spectrometry
  • [ISO-abbreviation] J. Am. Soc. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Z30RAY509F / Ergosterol
  •  go-up   go-down


15. Flannery RB Jr: Crisis intervention services and empirical data: lessons learned from the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2008;10(4):271-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crisis intervention services and empirical data: lessons learned from the Assaulted Staff Action Program (ASAP).
  • This paper reviews the lessons learned from the Assaulted Staff Action Program (ASAP) data base to illustrate how empirical data can meet the national standard of evidence-based care and improve the quality of services provided.
  • The ASAP data have demonstrated the safety and efficacy of ASAP as well as providing insights for risk management strategies in the changing face of patient violence.
  • [MeSH-major] Crisis Intervention. Empirical Research. Program Development. Violence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278143.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Rodríguez-Patrón Rodríguez R, Mayayo Dehesa T, Burgos Revilla FJ, Sanz Mayayo E, García González R: [Prognostic significance of PIN and Atypical Small Acinar Proliferation on transrectal ultrasound-guided prostate biopsy]. Actas Urol Esp; 2006 Apr;30(4):359-66
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of PIN and Atypical Small Acinar Proliferation on transrectal ultrasound-guided prostate biopsy].
  • OBJECTIVE: To review the incidence of PIN and Atypical Small Acinar Proliferation (ASAP) on first biopsy, the risk to find cancer on following biopsies and what is the importance given to this findings, analizing how frequently and how long after the initial finding this patients are rebiopsied.
  • PIN and ASAP are stable or slightly increase from 2 and 2,1% respectively on the first biopsy to more than 6% on the fourth and fifth ones.
  • Mean time between biopsies when ASAP or PIN are the initial findings is 180 +/- 221,6 and 264 +/- 213,8 days respectively.
  • Just 42 and 40% of patients with prior PIN or ASAP diagnose are rebiopsied.
  • CONCLUSIONS: Presence of PIN or ASAP implies a higher cancer risk on subsequent biopsies; in spite of that, less than half of them are biopsied again.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology. Surgery, Computer-Assisted. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838607.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


17. Aliu O, Chung KC: Readability of ASPS and ASAPS educational web sites: an analysis of consumer impact. Plast Reconstr Surg; 2010 Apr;125(4):1271-8
MedlinePlus Health Information. consumer health - Health Literacy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Readability of ASPS and ASAPS educational web sites: an analysis of consumer impact.
  • METHODS: The authors studied the readability of patient education materials related to common plastic surgery procedures from the American Society of Plastic Surgeons (ASPS) and the American Society for Aesthetic Plastic Surgery (ASAPS) Web sites and compared them with materials on similar topics from 10 popular health information-providing sites.
  • RESULTS: The authors found that all analyzed documents on the ASPS and ASAPS Web sites targeted to the consumers were rated to be more difficult than the recommended reading grade level for most American adults, and these documents were consistently among the most difficult to read when compared with the other health information Web sites.
  • Patient education material provided on ASPS and ASAPS Web sites should be written at recommended reading grade levels to ensure that it is readable and comprehensible to the targeted audience.

  • MedlinePlus Health Information. consumer health - Evaluating Health Information.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 2002 Nov;49(5):460-5 [12439011.001]
  • [Cites] Iowa Orthop J. 2002;22:103-7 [12180601.001]
  • [Cites] Am J Public Health. 2002 Aug;92(8):1278-83 [12144984.001]
  • [Cites] CA Cancer J Clin. 2002 May-Jun;52(3):134-49 [12018928.001]
  • [Cites] CA Cancer J Clin. 2002 May-Jun;52(3):130-3 [12018927.001]
  • [Cites] J Gen Intern Med. 2002 Mar;17(3):180-5 [11929503.001]
  • [Cites] JAMA. 2001 May 23-30;285(20):2612-21 [11368735.001]
  • [Cites] Prev Med. 2001 Apr;32(4):313-20 [11304092.001]
  • [Cites] Plast Reconstr Surg. 2001 Jan;107(1):171-6 [11176620.001]
  • [Cites] BMJ. 2000 Dec 16;321(7275):1511-5 [11118181.001]
  • [Cites] J Bone Joint Surg Am. 2000 Nov;82-A(11):1540-3 [11097441.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 2000 Jul;118(1):4-9 [10893465.001]
  • [Cites] Iowa Orthop J. 2003;23:80-2 [14575255.001]
  • [Cites] Respir Care. 2008 Oct;53(10):1310-5 [18811992.001]
  • [Cites] Patient Educ Couns. 2006 Oct;63(1-2):24-8 [16406474.001]
  • [Cites] Health Educ Behav. 2006 Jun;33(3):352-73 [16699125.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):381-90 [10430244.001]
  • [Cites] J Adolesc Health. 1999 Jun;24(6):403-11 [10401968.001]
  • [Cites] J Vasc Surg. 1999 Jul;30(1):84-91 [10394157.001]
  • [Cites] Hand Surg. 2004 Jul;9(1):29-33 [15368622.001]
  • [Cites] Br J Educ Psychol. 1983 Nov;53 (Pt 3):369-73 [6652037.001]
  • [Cites] J Child Psychol Psychiatry. 1985 May;26(3):407-21 [4008544.001]
  • [Cites] N Engl J Med. 1992 Jan 16;326(3):145-50 [1727544.001]
  • [Cites] J Am Board Fam Pract. 1992 May-Jun;5(3):257-64 [1580173.001]
  • [Cites] J Health Care Poor Underserved. 1994;5(2):99-111 [8043732.001]
  • [Cites] Oncol Nurs Forum. 1996 Sep;23(8):1305-12 [8883075.001]
  • [Cites] Clin Perform Qual Health Care. 1997 Apr-Jun;5(2):64-6 [10167213.001]
  • [Cites] BMJ. 1997 Jun 28;314(7098):1875-9 [9224132.001]
  • [Cites] Am J Public Health. 1997 Jun;87(6):1027-30 [9224190.001]
  • [Cites] Arch Intern Med. 1998 Jan 26;158(2):166-72 [9448555.001]
  • [Cites] Pediatrics. 1998 Jun;101(6):E2 [9606244.001]
  • [Cites] Chest. 1998 Oct;114(4):1008-15 [9792569.001]
  • (PMID = 20072085.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / K24 AR053120; None / None / / K24 AR053120-01A2; United States / NIAMS NIH HHS / AR / K24 AR053120-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS172906; NLM/ PMC2845740
  •  go-up   go-down


18. Venoux M, Basbous J, Berthenet C, Prigent C, Fernandez A, Lamb NJ, Rouquier S: ASAP is a novel substrate of the oncogenic mitotic kinase Aurora-A: phosphorylation on Ser625 is essential to spindle formation and mitosis. Hum Mol Genet; 2008 Jan 15;17(2):215-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASAP is a novel substrate of the oncogenic mitotic kinase Aurora-A: phosphorylation on Ser625 is essential to spindle formation and mitosis.
  • ASAP is a novel spindle-associated protein, the deregulation of which induces severe mitotic defects.
  • We show here that ASAP is a novel substrate of AurA kinase.
  • We have identified serine 625 as the major phosphorylation site for AurA in vivo and localized the phosphorylated form of ASAP to centrosomes from late G2 to telophase, and around the midbody during cytokinesis.
  • AurA depletion induces a proteasome-dependent degradation of ASAP.
  • ASAP depletion induces spindle defects rescued by the expression of the phosphorylation-mimetic mutant ASAP-S625E and not by the non-phosphorylatable mutant ASAP-S625A.
  • These results strongly indicate that the phosphorylation of ASAP on S625 by AurA is required for bipolar spindle assembly and is essential for a correct mitotic progression.
  • All together, these results suggest that we have identified a novel AurA substrate, pointing out ASAP as a new potential target for antitumoral drugs.

  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925329.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 452VLY9402 / Serine; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


19. Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM: Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol; 2005 Jan;173(1):70-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era.
  • PURPOSE: High grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in the sextant biopsy had been associated with a high risk of prostate cancer.
  • MATERIALS AND METHODS: From 1998 to 2003, 105 of 1,188 men had at least 1 repeat extended biopsy due to the presence of HGPIN (33 men) or ASAP (72 men) in a previous extended biopsy.
  • Median biopsy interval for HGPIN and ASAP was 15 and 10 weeks (p <0.05), respectively.
  • In men with ASAP 19 of 53 (36%, p <0.005) had cancer on 1st repeat biopsy, and 3 of 19 (16%) had cancer on 2nd repeat biopsy.
  • Patient age, digital rectal examination status, prostate specific antigen, free prostate specific antigen, number of cores and biopsy interval were not independent predictors of cancer in men with ASAP.
  • ASAP continues to be associated with a high risk of cancer and requires at least 1 repeat biopsy using the extended biopsy scheme.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Humans. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592031.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


20. Scattoni V, Roscigno M, Freschi M, Dehò F, Raber M, Briganti A, Fantini G, Nava L, Montorsi F, Rigatti P: Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. Arch Ital Urol Androl; 2005 Mar;77(1):31-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.
  • OBJECTIVE: To evaluate the clinical and histopathologic factors that may help to predict cancer detection by means of extended repeated prostate needle biopsies in patients with Jumma atypical small acinar proliferation (ASAP) results on initial prostate biopsy.
  • MATERIALS AND METHODS: From 1998 to September 2003, 105 out of 121 (86%) patients with a diagnosis of ASAP after a first set of 10 to 12 systematic biopsies, were rebiopsied using the same technique plus additional biopsies on the ASAP site (mean number of repeat biopsy samples, 12.6).
  • RESULTS: On initial biopsy, a concomitant HGPIN was present in 18 patients (17%) with ASAP The overall cancer detection rate in those who underwent two or three sets of biopsies was 39% (41/105); it was 35% (37/105) and 21% (4/19) in second and third biopsies, respectively.
  • The overall cancer detection rate was higher in patients who had ASAP associated with HGPIN (50%) compared with patients who had isolated ASAP (37%) (p = 0.3).
  • Statistical analysis showed that levels of prostate-specific antigen (PSA), PSA density, prostatic volume, digital rectal examination results, transrectal ultrasound findings, time until rebiopsy (less vs. more than 6 months), and histological level of suspicion were not significant predictors of prostate cancer at the time of rebiopsy.
  • In a univariate analysis, the mean prostate volume was statistically different in patients with cancer compared with those without (56.4 +/- 6.3 and 78.9 +/- 5.3 respectively; p = 0.009), but only in the group of patients who had isolated ASAP In these patients, the rate of cancer detection was significantly higher in patients who had a prostatic volume less than 60 mL (56%) than in patients with a prostatic volume greater than or equal to 60 mL (27%) (p = 0.03).
  • CONCLUSIONS: Patients with an initial ASAP diagnosis after extended biopsies had an overall cancer detection rate less than 40% after two sets of extended biopsy.
  • Despite the extended rebiopsy plus the additional biopsies targeted to the ASAP lesion, the detection rate was lower for patients with a larger prostate than those with a smaller prostate.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906787.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Schlesinger C, Bostwick DG, Iczkowski KA: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol; 2005 Sep;29(9):1201-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice.
  • In earlier studies, prostate cancer (PCa) has been reported to appear in 21% to 48% of subsequent biopsies for isolated high-grade prostatic intraepithelial neoplasia (PIN) and in 34% to 60% for isolated atypical small acinar proliferation suspicious for, but not diagnostic of, malignancy (ASAP).
  • The study group consisted of 336 men with initial diagnoses of PIN (n = 204), ASAP (n = 78), or both lesions (n = 54) who underwent at least one repeat biopsy.
  • Mean follow-up intervals in months were 6.0 for PIN, 3.8 for ASAP, and 4.9 for PIN/ASAP.
  • The predictive value of ASAP was significantly higher than that for PIN (P = 0.0188).
  • In 13 ASAP studies, mean PCa detection on follow-up was 45% until 1996 and 39% from 1997 to present.
  • PIN/ASAP predicted PCa in 33% of cases in our study, similar to ASAP alone (P = 0.65) and had a mean predictive value of 44% in the literature.
  • 1) extended biopsy techniques that yield higher rates of initial cancer detection, 2) lower detection rate for the remaining small cancers that may accompany PIN, and 3) remaining PIN cases may lack concomitant cancer.
  • [MeSH-major] Precancerous Conditions / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2005 Nov;29(11):1548
  • (PMID = 16096410.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Zydel F, Trimpin S, McEwen CN: Laserspray ionization using an atmospheric solids analysis probe for sample introduction. J Am Soc Mass Spectrom; 2010 Nov;21(11):1889-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laserspray ionization using an atmospheric solids analysis probe for sample introduction.
  • A newly introduced high sensitivity laserspray (LSI) mass spectrometry (MS) method that uses laser ablation of a matrix/analyte mixture at atmospheric pressure (AP) to obtain multiply charged ions from nonvolatile as well as high-mass compounds is now implemented using a simple probe device.
  • The probe used in the LSI approach was originally designed for sample introduction into an AP ionization source using the atmospheric solids analysis probe (ASAP) method.
  • Here we demonstrate rapid analysis by placing four peptide and protein samples on a single melting point tube.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • [Cites] Anal Chem. 1997 Jul 1;69(13):2525-9 [9212711.001]
  • [Cites] Anal Chem. 2009 Nov 1;81(21):9158-62 [19807111.001]
  • [Cites] Anal Chem. 2010 Jun 15;82(12):4998-5001 [20469839.001]
  • [Cites] Anal Chem. 2002 Apr 15;74(8):1891-5 [11985323.001]
  • [Cites] J Am Soc Mass Spectrom. 2010 Jul;21(7):1260-4 [20435486.001]
  • [Cites] Anal Chem. 2008 Apr 15;80(8):2646-53 [18345693.001]
  • [Cites] Mol Cell Proteomics. 2010 Feb;9(2):362-7 [19955086.001]
  • [Cites] Anal Chem. 2010 Jan 1;82(1):11-5 [19904915.001]
  • [Cites] Rapid Commun Mass Spectrom. 2009 Jul;23(13):1989-92 [19504481.001]
  • [Cites] J Am Soc Mass Spectrom. 2007 Jul;18(7):1274-8 [17482834.001]
  • [Cites] Anal Chem. 2005 Dec 1;77(23):7826-31 [16316194.001]
  • [Cites] Rapid Commun Mass Spectrom. 2009 Sep;23(18):3023-7 [19685478.001]
  • [Cites] Anal Chem. 2008 Sep 1;80(17):6773-8 [18656949.001]
  • [Cites] Anal Chem. 2007 Jul 15;79(14):5484-8 [17569505.001]
  • [Cites] Anal Chim Acta. 2009 Nov 3;654(1):20-5 [19850163.001]
  • [Cites] Anal Chem. 1988 Oct 15;60(20):2299-301 [3239801.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Nov;10(11):1105-10 [10536817.001]
  • (PMID = 20732821.001).
  • [ISSN] 1879-1123
  • [Journal-full-title] Journal of the American Society for Mass Spectrometry
  • [ISO-abbreviation] J. Am. Soc. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kim KH, Kim YB, Lee JK, Kim YJ, Jung TY: Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer. Korean J Urol; 2010 Jun;51(6):398-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer.
  • PURPOSE: The incidence of adenocarcinoma on a subsequent biopsy following a diagnosis of atypical small acinar proliferation (ASAP) ranges from 34% to 60%.
  • We reexamined radical prostatectomy (RP) specimens of patients diagnosed as having synchronous ASAP with prostate cancer (PCa) to evaluate pathological entities and the clinical significance of ASAP.
  • MATERIALS AND METHODS: From January 2007 to December 2008, a total of 118 patients who had been diagnosed with adenocarcinoma on prostate needle biopsy underwent RP.
  • Forty-six of the 118 patients (39%) were diagnosed as having synchronous ASAP with PCa on the prostate needle biopsy.
  • Using whole-mount sections and prostate mapping, we evaluated the RP specimens that were close sections to the ASAP on prostate needle biopsy.
  • RESULTS: Thirty-six of the 46 patients (78%) were diagnosed as having adenocarcinoma at sites of ASAP on the initial prostate needle biopsies.
  • CONCLUSIONS: Most ASAP on initial prostate needle biopsy was a true pathological entity, in other words, prostatic adenocarcinoma.
  • Aggressive approaches including more extended repeat biopsy with additional biopsy of the site of the ASAP are needed to diagnose PCa in patients with ASAP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 2009 Oct;27(5):587-92 [19373471.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1306-13 [18083294.001]
  • [Cites] BJU Int. 2007 Apr;99(4):780-5 [17378841.001]
  • [Cites] BJU Int. 2007 Jan;99(1):49-52 [17227491.001]
  • [Cites] Eur Urol. 2006 Oct;50(4):666-74 [16930809.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Apr;28(2):104-10 [16637513.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):49-53; discussion 53 [16314035.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Int J Urol. 2005 Apr;12(4):353-60 [15948721.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Virchows Arch. 1997 Jan;430(1):1-16 [9037309.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] J Urol. 1989 Jul;142(1):71-4; discussion 74-5 [2659827.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):557-60 [15086303.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):370-2 [12853777.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):68-71 [12588600.001]
  • [Cites] Urology. 2002 Nov;60(5):851-4 [12429314.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] BJU Int. 2001 Jul;88(2):147-57 [11446873.001]
  • [Cites] Urol Oncol. 2009 Sep-Oct;27(5):509-13 [18625570.001]
  • (PMID = 20577606.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890056
  • [Keywords] NOTNLM ; Needle biopsy / Prostatectomy / Prostatic neoplasms / Surgical pathology
  •  go-up   go-down


24. Amin MM, Jeyaganth S, Fahmy N, Bégin L, Aronson S, Jacobson S, Tanguay S, Aprikian AG: Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can Urol Assoc J; 2007 Sep;1(3):245-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation.
  • INTRODUCTION: To evaluate the predictors of prostate cancer in follow-up of patients diagnosed on initial biopsy with high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP).
  • METHODS: We studied 201 patients with HGPIN and 22 patients with ASAP on initial prostatic biopsy who had subsequent prostatic biopsies.
  • RESULTS: On subsequent biopsies, the rate of prostate cancer was 21.9% (44/201) in HGPIN patients.
  • In ASAP patients, the cancer detection rate was 13/22 (59.1%), all of whom were found on the first follow-up biopsy.
  • There was a statistically significant difference between the cancer detection rate in ASAP and HGPIN patients (p < 0.001).
  • Multivariate analysis showed that the independent predictors of cancer were the number of cores in the initial biopsy, the number of cores (> 10) in the follow-up biopsy and a prostate specific antigen (PSA) density of >/= 0.15 (odds ratio 0.77, 3.46 and 2.7,8 respectively; p < 0.04).
  • Conversely, in ASAP patients none of these variables were found to be associated with cancer diagnosis.
  • CONCLUSION: ASAP is a strong predictive factor associated with cancer when compared with HGPIN.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Jul;166(1):86-91; discussion 91-2 [11435830.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Urology. 2001 Feb;57(2):296-300 [11182340.001]
  • [Cites] BJU Int. 2001 Jan;87(1):70-4 [11201402.001]
  • [Cites] Urology. 2000 Apr;55(4):553-9 [10736500.001]
  • [Cites] J Urol. 2000 Jan;163(1):163-6; discussion 166-7 [10604337.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):145-52 [9921986.001]
  • [Cites] Am J Clin Pathol. 1997 Dec;108(6):633-40 [9384444.001]
  • [Cites] J Urol. 1997 Jan;157(1):199-202; discussion 202-3 [8976250.001]
  • [Cites] J Urol. 1996 Aug;156(2 Pt 1):460-2; discussion 462-3 [8683703.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Br J Urol. 1995 Sep;76(3):355-9 [7551846.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1415-8 [12352407.001]
  • [Cites] Urol Oncol. 2003 Mar-Apr;21(2):135-40 [12856642.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):68-71 [12588600.001]
  • [Cites] Eur Urol. 2002 Aug;42(2):93-103 [12160578.001]
  • [Cites] Urology. 2002 Feb;59(2):261-5 [11834399.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • (PMID = 18542796.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422970
  •  go-up   go-down


25. Mancuso PA, Chabert C, Chin P, Kovac P, Skyring T, Watt WH, Napaki S: Prostate cancer detection in men with an initial diagnosis of atypical small acinar proliferation. BJU Int; 2007 Jan;99(1):49-52
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer detection in men with an initial diagnosis of atypical small acinar proliferation.
  • OBJECTIVE: To determine the subsequent prostatic adenocarcinoma detection rate amongst men with an initial diagnosis of atypical small acinar proliferation (ASAP).
  • PATIENTS AND METHODS: We reviewed the Illawarra Prostate Pathology Database over a 10-year period (January 1994 to January 2004) for specimens diagnosed as ASAP.
  • RESULTS: Of 61 cases of ASAP, there were complete follow-up data for 31.
  • The incidence of prostatic adenocarcinoma in this group was 17/31 (55%).
  • CONCLUSION: This study showed a detection rate for prostatic adenocarcinoma of 55% after an initial diagnosis of ASAP, which indicates that an initial diagnosis of ASAP mandates re-biopsy.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Cell Proliferation. Cohort Studies. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Prostate-Specific Antigen / blood. Retrospective Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227491.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


26. Toledo F, Liu CW, Lee CJ, Wahl GM: RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res; 2006 Jul 26;34(13):e92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses.
  • But more importantly, the approach was Adapted for targeting in Somatic cells to Accelerate Phenotyping (RMCE-ASAP).
  • RMCE-ASAP combines inverted heterologous recombinase target sites, a positive/negative selection marker that preserves the germline capacity of ES cells, and the power of mouse genetics.
  • These general principles should make RMCE-ASAP applicable to any locus.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41028-33 [12909629.001]
  • [Cites] Nat Biotechnol. 2003 Mar;21(3):321-4 [12563279.001]
  • [Cites] Genesis. 2004 Feb;38(2):87-92 [14994271.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):8884-94 [15456863.001]
  • [Cites] Biochim Biophys Acta. 1988 Sep 7;950(3):395-402 [3048409.001]
  • [Cites] Nucleic Acids Res. 1989 Jan 11;17(1):147-61 [2783482.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3332-44 [9345015.001]
  • [Cites] Curr Biol. 1998 Jan 29;8(3):145-55 [9443911.001]
  • [Cites] J Mol Biol. 1999 Oct 1;292(4):779-85 [10525404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10188-93 [16006521.001]
  • [Cites] Genesis. 2005 Aug;42(4):229-35 [16028230.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):e147 [16204450.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(2):605-16 [16382151.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):273-85 [16616333.001]
  • [Cites] Genesis. 2000 Sep;28(1):31-5 [11020714.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):260-71 [11237328.001]
  • [Cites] Nat Rev Genet. 2001 Oct;2(10):743-55 [11584291.001]
  • [Cites] Trends Cell Biol. 2002 Jun;12(6):281-7 [12074888.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 15;30(14):3067-77 [12136089.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):976-84 [14729946.001]
  • (PMID = 16870721.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA061449; United States / NCI NIH HHS / CA / R01 CA100845; United States / NCI NIH HHS / CA / CA061449; United States / NCI NIH HHS / CA / CA100845
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Viral Proteins; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC1540739
  •  go-up   go-down


27. Ding J, Erdal S, Borlawsky T, Liu J, Golden-Kreutz D, Kamal J, Payne PR: The design of a pre-encounter clinical trial screening tool: ASAP. AMIA Annu Symp Proc; 2008 Nov 06;:931
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The design of a pre-encounter clinical trial screening tool: ASAP.
  • In order to increase the efficiency of such processes, we have developed a web-based system, called Advanced Screening for Active Protocols (ASAP).

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998826.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR025755
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Bruns EA, Perraud V, Greaves J, Finlayson-Pitts BJ: Atmospheric solids analysis probe mass spectrometry: a new approach for airborne particle analysis. Anal Chem; 2010 Jul 15;82(14):5922-7
Hazardous Substances Data Bank. ALPHA-PINENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atmospheric solids analysis probe mass spectrometry: a new approach for airborne particle analysis.
  • In this study, atmospheric solids analysis probe mass spectrometry (ASAP-MS) is applied for the first time to the identification of organics in particles from laboratory systems as well as from ambient air.
  • Particles were collected by impaction on ZnSe disks, analyzed by Fourier transform-infrared spectroscopy (FT-IR) and then transferred to an ASAP-MS probe for further analysis.
  • ASAP-MS data for the laboratory-generated samples show peaks from well-known products of these reactions, and higher molecular weight oligomers are present in both laboratory and ambient samples.
  • In addition, a dedicated instrument is not required for particle analysis.
  • This work establishes that ASAP-MS will be useful for identification of organic components of SOA in a variety of field and laboratory studies.
  • [MeSH-major] Aerosols / chemistry. Air Pollutants / analysis. Mass Spectrometry / methods. Particulate Matter / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OZONE .
  • Hazardous Substances Data Bank. ISOPRENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568716.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Letter; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Air Pollutants; 0 / Butadienes; 0 / Hemiterpenes; 0 / Monoterpenes; 0 / Particulate Matter; 0 / Pentanes; 0A62964IBU / isoprene; 66H7ZZK23N / Ozone; JPF3YI7O34 / alpha-pinene
  •  go-up   go-down


29. Kim N, Alekseyenko AV, Roy M, Lee C: The ASAP II database: analysis and comparative genomics of alternative splicing in 15 animal species. Nucleic Acids Res; 2007 Jan;35(Database issue):D93-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ASAP II database: analysis and comparative genomics of alternative splicing in 15 animal species.
  • We have greatly expanded the Alternative Splicing Annotation Project (ASAP) database: (i) its human alternative splicing data are expanded approximately 3-fold over the previous ASAP database, to nearly 90,000 distinct alternative splicing events;.
  • ASAP II provides a new web interface enabling more detailed exploration of the data, and integrating comparative genomics information with alternative splicing data.
  • We provide a set of tools for advanced data-mining of ASAP II with Pygr (the Python Graph Database Framework for Bioinformatics) including powerful features such as graph query, multigenome alignment query, etc.
  • ASAP II is available at http://www.bioinformatics.ucla.edu/ASAP2.

  • COS Scholar Universe. author profiles.
  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5635-43 [14500827.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):177-80 [12730695.001]
  • [Cites] FEBS Lett. 2003 Dec 18;555(3):572-8 [14675776.001]
  • [Cites] Science. 2003 Dec 19;302(5653):2141-4 [14684825.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1261-9 [14982953.001]
  • [Cites] Genome Res. 2004 Mar;14(3):426-41 [14962984.001]
  • [Cites] Genome Res. 2004 Apr;14(4):708-15 [15060014.001]
  • [Cites] J Mol Med (Berl). 1997 Oct;75(10):694-8 [9382993.001]
  • [Cites] Nucleic Acids Res. 2004;32(22):e180 [15598820.001]
  • [Cites] BMC Bioinformatics. 2004 Dec 7;5:189 [15581431.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D501-4 [15608248.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D54-8 [15608257.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D75-9 [15608289.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D556-61 [16381931.001]
  • [Cites] Genome Res. 2005 Apr;15(4):566-76 [15805497.001]
  • [Cites] Bioinformatics. 2005 Apr 15;21(8):1358-64 [15673565.001]
  • [Cites] IDrugs. 2005 Sep;8(9):725-9 [16118693.001]
  • [Cites] Nucleic Acids Res. 2005;33(16):5026-33 [16147986.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2198-208 [16049198.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D16-20 [16381837.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D590-8 [16381938.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D56-62 [16381932.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D46-55 [16381912.001]
  • [Cites] PLoS Genet. 2005 Sep;1(3):e34 [16170410.001]
  • [Cites] Mol Biol Evol. 2006 Mar;23(3):675-82 [16368777.001]
  • [Cites] Genetics. 2006 Jul;173(3):1787-91 [16702427.001]
  • [Cites] Trends Genet. 2001 Feb;17(2):100-7 [11173120.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):2850-9 [11433032.001]
  • [Cites] Trends Genet. 2002 Apr;18(4):186-93 [11932019.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):236-43 [12110900.001]
  • [Cites] Nucleic Acids Res. 2002 Sep 1;30(17):3754-66 [12202761.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1837-45 [12466287.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):101-5 [12519958.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • (PMID = 17108355.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / U54 RR021813
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA Splice Sites
  • [Other-IDs] NLM/ PMC1669709
  •  go-up   go-down


30. Mallén E, Gil P, Sancho C, Jesús Gil M, Allepuz C, Borque A, Del Agua C, Angel Rioja L: Atypical small acinar proliferation: review of a series of 64 patients. Scand J Urol Nephrol; 2006;40(4):272-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: review of a series of 64 patients.
  • OBJECTIVE: To study the evolution of 64 patients initially diagnosed with ASAP (atypical small acinar proliferation).
  • MATERIAL AND METHODS: Between 1998 and the end of 2003, 64 patients were diagnosed at our centre with ASAP.
  • RESULTS: The mean age of the patients assessed was 69 years (SD 6.4 years), the median prostate-specific antigen (PSA) level was 7.1 ng/ml (range 2-39 ng/ml) and 25% of the patients had a suspicious rectal examination.
  • At re-biopsy, we diagnosed 27 patients (42%) with prostate adenocarcinoma.
  • Radical prostatectomy was applied to 20/28 patients (71%) diagnosed with prostate cancer.
  • CONCLUSIONS: In our experience, a pathological result of ASAP is associated with a definitive diagnosis of prostate cancer in 42% of cases.
  • We therefore systematically perform repeat biopsies on all patients with a histological result of ASAP.
  • [MeSH-major] Prostatic Diseases / diagnosis
  • [MeSH-minor] Aged. Biopsy. Cell Proliferation. Humans. Male. Prostate-Specific Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916766.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


31. Pascual Mateo C, Luján Galán M, Rodríguez García N, Llanes González L, Berenguer Sánchez A: [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer]. Actas Urol Esp; 2008 Jul-Aug;32(7):680-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer].
  • [Transliterated title] Significado clínico de la neoplasia intraepitelial prostática y de la proliferación acinar focal atípica: relación con el cáncer de próstata.
  • INTRODUCTION: Prostatic intraepithelial neoplasia (PIN) and atypical small acinar proliferation (ASAP) in the setting of prostatic needle biopsies are considered premalignant although questions still remain.
  • MATERIAL AND METHODS: We collected 138 subjects (108 PIN, 30 ASAP); in 67% we performed a second biopsy and the rate of cancer in this late biopsy were 19% and 27% respectively.
  • We cannot identify any clinical factor to predict the finding of cancer in the re-biopsy (PSA, age, digital rectal examination, prostatic volume).
  • RESULTS: In the follow-up, we observed higher rates of cancer for the ASAP; the finding of ASAP was the single clinical or histopathological factor that was an independent predictor of cancer.
  • CONCLUSIONS: We observed that the finding of ASAP was an indication for re-biopsy because of the higher rates of cancer; on the contrary, the paper of PIN in the prostatic needle biopsy still requires further investigation.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Proliferation. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788482.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


32. Andrès E, Reichert S, Gass R, Brandt C: A French national research project to the creation of an auscultation's school: the ASAP project. Eur J Intern Med; 2009 May;20(3):323-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A French national research project to the creation of an auscultation's school: the ASAP project.
  • This paper describes an ambitious study of in the so-called ASAP project or "Analyse de Sons Auscultatoires et Pathologiques".
  • ASAP is a 3-year-long French collaborative project developed in the context of the News Technologies of Information and Communication.
  • ASAP aims at making evolve the auscultation technics: by 1) the development objective tools for the analyse of auscultation sounds: electronic stethoscopes paired with computing device;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19393502.001).
  • [ISSN] 1879-0828
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Twohig M, Skilton SJ, Fujimoto G, Ellor N, Plumb RS: Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe. Drug Test Anal; 2010 Feb;2(2):45-50
Hazardous Substances Data Bank. TADALAFIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.
  • An Atmospheric Solids Analysis Probe (ASAP) was used for the direct analysis of the counterfeit pharmaceuticals and herbal products.
  • Using the ASAP combined with time-of-flight mass spectrometry (TOF MS) it was possible to detect fraudulent counterfeit tablets.
  • Detecting adulteration for five herbal supplements marketed as natural alternatives to PDE-5 inhibitors was also possible using the ASAP.

  • MedlinePlus Health Information. consumer health - Drug Safety.
  • Hazardous Substances Data Bank. SILDENAFIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [ErratumIn] Drug Test Anal. 2011 Mar;3(3):191-3
  • (PMID = 20878886.001).
  • [ISSN] 1942-7611
  • [Journal-full-title] Drug testing and analysis
  • [ISO-abbreviation] Drug Test Anal
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbolines; 0 / Counterfeit Drugs; 0 / Phosphodiesterase 5 Inhibitors; 0 / Piperazines; 0 / Plant Preparations; 0 / Purines; 0 / Sulfones; 742SXX0ICT / Tadalafil; BW9B0ZE037 / Sildenafil Citrate
  •  go-up   go-down


34. Flannery RB Jr, Juliano J, Cronin S, Walker AP: Characteristics of assaultive psychiatric patients: fifteen-year analysis of the Assaulted Staff Action Program (ASAP). Psychiatr Q; 2006;77(3):239-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of assaultive psychiatric patients: fifteen-year analysis of the Assaulted Staff Action Program (ASAP).
  • This study reports on a fifteen-year longitudinal analysis of the characteristics of assaultive patients in one public-sector mental health care system.
  • The data were gathered within the context of the Assaulted Staff Action Program (ASAP), a crisis intervention service for staff victims.
  • Both groups had appreciable histories of violence toward others, personal victimization, and substance use disorders.
  • [MeSH-major] Crisis Intervention. Health Personnel / psychology. Mental Disorders / epidemiology. Mental Disorders / psychology. Patients / psychology. Patients / statistics & numerical data. Professional-Patient Relations. Program Development. Program Evaluation. Stress Disorders, Post-Traumatic / psychology. Stress Disorders, Post-Traumatic / therapy. Violence

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Harv Rev Psychiatry. 2000 Nov;8(5):261-70 [11118235.001]
  • [Cites] Psychol Sci Public Interest. 2003 Nov;4(2):45-79 [26151755.001]
  • [Cites] AAOHN J. 1992 May;40(5):219-28 [1580948.001]
  • [Cites] J Ment Health Adm. 1994 Winter;21(1):24-31 [10131885.001]
  • [Cites] Psychiatr Q. 2002 Fall;73(3):229-37 [12143084.001]
  • [Cites] Psychiatr Q. 2002 Spring;73(1):59-69 [11780599.001]
  • [Cites] Psychiatr Q. 2005 Winter;76(4):317-26 [16217626.001]
  • [Cites] AAOHN J. 1996 Dec;44(12):575-80 [9043223.001]
  • [Cites] J Occup Environ Med. 1998 Aug;40(8):707-13 [9729754.001]
  • [Cites] Hosp Community Psychiatry. 1985 Jun;36(6):652-7 [4007819.001]
  • [Cites] Int J Emerg Ment Health. 2000 Fall;2(4):241-7 [11217155.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2001 May-Jun;16(3):153-6 [11398563.001]
  • [Cites] Am Psychol. 1995 Dec;50(12):965-74 [8561380.001]
  • [Cites] Hosp Community Psychiatry. 1991 Jun;42(6):585-90 [1864567.001]
  • [Cites] J Psychosoc Nurs Ment Health Serv. 1991 May;29(5):21-6 [2066912.001]
  • [Cites] Hosp Community Psychiatry. 1981 Jul;32(7):497-8 [7239475.001]
  • (PMID = 16977513.001).
  • [ISSN] 0033-2720
  • [Journal-full-title] The Psychiatric quarterly
  • [ISO-abbreviation] Psychiatr Q
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Scattoni V, Roscigno M, Freschi M, Briganti A, Fantini GV, Bertini R, Salonia A, Montorsi F, Rigatti P: Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology; 2005 Nov;66(5):1043-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies.
  • OBJECTIVES: To evaluate the factors that predict prostate cancer detection by means of 10 to 12 core repeat biopsies in patients with atypical small acinar proliferation (ASAP) results on initial biopsy.
  • METHODS: From 1998 to 2004, 110 of 127 patients (87%) with a diagnosis of ASAP were rebiopsied with the same technique plus additional biopsies on the ASAP site (12.6 +/- 1.1 cores [mean +/- standard deviation]).
  • RESULTS: On initial biopsy, a concomitant high-grade prostatic intraepithelial neoplasia (HGPIN) was present in 26 patients (23%) with ASAP.
  • The overall cancer detection rate was significantly higher in patients who had ASAP associated with HGPIN (58%), compared with patients who had isolated ASAP (35%; P = 0.04).
  • In the group of patients who had isolated ASAP, the rate of cancer detection was significantly higher in patients who had a prostatic volume less than 50 mL (56%) than in patients with a prostatic volume of 50 mL or more (27%; P = 0.03).
  • CONCLUSIONS: The cancer detection rate was significantly higher in patients with an ASAP associated with HGPIN on initial biopsy than in patients with isolated ASAP.
  • In ASAP patients, the detection rate was lower for patients with a larger prostate than in those with a smaller prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286121.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Strand CL, Aponte SL, Chatterjee M, Engelbach LM, Fromowitz FB, Guo Y, Iorga PG, Kartika G, Li R, Mahapatro D, Pai UL, Romeroacaces GM, Sharaan ME, Vara ML, Riba AK: Improved resolution of diagnostic problems in selected prostate needle biopsy specimens by using the ASAP workup: a prospective study of interval sections vs new recut sections. Am J Clin Pathol; 2010 Aug;134(2):293-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved resolution of diagnostic problems in selected prostate needle biopsy specimens by using the ASAP workup: a prospective study of interval sections vs new recut sections.
  • This study assessed the value of an atypical small acinar proliferation (ASAP) workup consisting of preparing new recut sections from the paraffin block and performing H&E-stained sections and immunostains (using the antibody cocktail for p63, cytokeratins 5 and 14, and alpha-methylacyl coenzyme A racemase) on the slides.
  • We compared the ASAP workup with the interval workup, the common practice of performing the same immunostains on the saved interval sections, in 105 cases because of focal glandular atypia on the original H&E-stained sections.
  • There were no specimens in which only the interval workup showed a changed diagnosis, but there were 23 specimens (21.9%) in which the preliminary diagnosis was changed to a definitive diagnosis of carcinoma (10 specimens) or a specific benign diagnosis (13 specimens) based solely on the findings of the ASAP workup.
  • The ASAP workup is recommended as a very useful histologic tool for resolving diagnostic problems in prostate needle biopsy specimens.
  • [MeSH-major] Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660334.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Iczkowski KA: Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med; 2006 Jun;130(6):835-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains.
  • CONTEXT: The past decade has brought major changes in prostate biopsy sampling, interpretation, and reporting.
  • OBJECTIVE: To summarize current information on diagnostic decision making, Gleason grading, "atypical" diagnoses, and use of immunostaining.
  • CONCLUSIONS: Diagnosis begins by evaluating a focus of atypical single-cell layer lined acini according to the 3 minimal diagnostic criteria for cancer: an infiltrative pattern, nuclear enlargement and hyperchromasia, and prominent nucleoli.
  • Atypical small acinar proliferation suspicious for malignancy designates foci that have either qualitative or quantitative limitations in atypia precluding a definite cancer diagnosis.
  • Isolated high-grade prostatic intraepithelial neoplasia has a 3% to 14% incidence and predicts cancer on repeat biopsy in 23% of cases.
  • Immunostaining for a marker of benign prostate (cytoplasmic keratin 34betaE12 or nuclear p63) and a marker of cancer (alpha-methylacyl coA racemase, clone P504S) may or may not resolve atypical small acinar proliferation diagnoses.
  • Performance of 34betaE12 and P504S immunostains resolved 76% of atypical small acinar proliferation diagnoses per consensus of 3 urologic pathologists studied; a technical limitation is preservation of the focus in question on the levels used for immunostaining.
  • [MeSH-major] Immunohistochemistry / methods. Precancerous Conditions / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Cell Nucleus / pathology. Cell Proliferation. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740037.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


38. Mearini L, Costantini E, Bellezza G, Cavaliere A, Zucchi A, Bini V, Porena M: Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int; 2008;81(1):29-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation?
  • INTRODUCTION: Tissue samples from prostate biopsy may contain atypical small acinar proliferation (ASAP): present guidelines recommend a repeat biopsy policy.
  • MATERIALS AND METHODS: From 1999 to 2005, 1,274 patients underwent a prostate biopsy: in 5.9% ASAP was found, and patients underwent a second biopsy.
  • Uni- and multivariate analysis compared the clinical patterns of cancer patients with the no cancer group at second biopsy.
  • RESULTS: Univariate analysis showed significant differences in PSA ratio density, prostate volume, final PSA values and Delta PSA; at multivariate logistic regression analysis, only PSA ratio (OR = 0.743, 95% CI 0.620-0.891) and prostate volume (OR = 0.960, 95% CI 0.924-0.998) were predictive of malignancy.
  • CONCLUSIONS: In our experience, PSA ratio and prostate volume seem to be independent predictors of prostate cancer at re-biopsy.
  • [MeSH-major] Cell Proliferation. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Male. Medical Oncology / methods. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prostate-Specific Antigen / biosynthesis. ROC Curve. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18645268.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


39. Twohig M, Shockcor JP, Wilson ID, Nicholson JK, Plumb RS: Use of an atmospheric solids analysis probe (ASAP) for high throughput screening of biological fluids: preliminary applications on urine and bile. J Proteome Res; 2010 Jul 2;9(7):3590-7
Hazardous Substances Data Bank. METHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of an atmospheric solids analysis probe (ASAP) for high throughput screening of biological fluids: preliminary applications on urine and bile.
  • A hybrid quadrupole orthogonal time-of-flight mass spectrometer (QToF) equipped with a solids analysis probe (atmospheric solids analysis probe-mass spectrometry (ASAP-MS)) has been applied to the high throughput qualitative analysis of bile (rat and dog) and urine (rat) samples.
  • The metabolic profiles generated by ASAP-MS was less comprehensive than that provided by liquid chromatography (LC) or gas chromatography-mass spectrometry (GC-MS) metabonomic profiling, though simple types of sample preparation were found to increase the range of ions detected for bile (a complex, multicompartment sample type).
  • While unsuited to biomarker discovery, ASAP-MS of these biofluids generated sufficiently complex metabolic fingerprints to enable them to be distinguished from each other using multivariate statistical methods such as principal components analysis (PCA).
  • [MeSH-minor] Animals. Atmosphere. Dogs. Metabolome. Methanol. Multivariate Analysis. Principal Component Analysis. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450223.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Y4S76JWI15 / Methanol
  •  go-up   go-down


40. Newell KJ, Amrhein JF, Desai RJ, Middlebrook PF, Webster TM, Sawka BW, Rudrick BF: Prostate gland biopsies and prostatectomies: an Ontario community hospital experience. Can Urol Assoc J; 2008 Oct;2(5):518-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate gland biopsies and prostatectomies: an Ontario community hospital experience.
  • OBJECTIVE: Transrectal ultrasound-guided core biopsies of the prostate gland and prostatectomies have become common procedures at many community hospitals in Canada, especially in the era of serum prostate-specific antigen (PSA) screening for prostate cancer.
  • The Gleason grading of prostate cancer in biopsies and prostatectomies is a major determinant used for treatment planning.
  • There is evidence in the literature that suggests important discordance between community hospital pathologists and urological pathologists with respect to the Gleason grading of prostate cancer.
  • Our objective was to determine the diagnostic rates and Gleason scoring patterns for prostate gland biopsies and prostatectomies at our institution compared with the literature.
  • METHODS: We conducted a retrospective review of all prostate gland biopsies and prostatectomies performed at the Grey Bruce Health Services from January 2005 to September 2005.
  • The rates of diagnosis from prostate gland biopsies of benign (17.6%), high-grade prostatic intraepithelial neoplasia (11.0%), atypical small acinar proliferation suspicious for invasive malignancy (13.2%) and invasive prostatic adenocarcinoma (58.2%) at our institution were significantly different than those reported in the literature (p < 0.001).
  • CONCLUSION: Our results showed a significant difference in prostate gland biopsy categorical diagnoses compared with the literature.
  • There were also significant differences in categorical diagnoses of prostate gland biopsies among the community hospital pathologists in our study.
  • We would encourage other community hospital pathologists, in collaboration with their urologists, to review periodically their prostate gland pathology practices in an attempt to improve the uniformity of diagnoses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2007 Mar;177(3):903-6 [17296372.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1818-23 [11042578.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Histopathology. 2006 May;48(6):655-62 [16681680.001]
  • [Cites] Histopathology. 2006 May;48(6):644-54 [16681679.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1004-10 [16048389.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):228-34 [15475927.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):687-92 [10420224.001]
  • [Cites] Urology. 1998 Feb;51(2):186-95 [9495696.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):566-76 [9158682.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):851-7 [8669533.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1007-8 [12873176.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):81-8 [11172299.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] J Urol. 2006 Sep;176(3):979-84; discussion 984 [16890675.001]
  • (PMID = 18953449.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2572237
  •  go-up   go-down


41. Ryu JH, Kim YB, Lee JK, Kim YJ, Jung TY: Predictive factors of prostate cancer at repeat biopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate. Korean J Urol; 2010 Nov;51(11):752-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of prostate cancer at repeat biopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate.
  • PURPOSE: The factors that predict prostate cancer detection on repeat biopsy were evaluated in patients with atypical small acinar proliferation (ASAP) on the initial biopsy.
  • MATERIALS AND METHODS: From 2003 to 2008, 3,130 men with suspected prostate cancer underwent a prostate needle biopsy, and 244 (7.8%) were diagnosed as having ASAP.
  • They were classified into a prostate cancer group and a noncancer group according to the final pathological diagnosis.
  • The database of rebiopsied patients included age, initial prostate-specific antigen (PSA), PSA density (PSAD), PSA velocity (PSAV), total prostate volume (TPV), and transitional zone volume of the prostate (TZV).
  • RESULTS: A total of 57 patients (33.5%) with ASAP were ultimately shown to have prostate cancer.
  • Univariate analysis showed that PSAD (p=0.002), PSAV (p=0.001), TPV (p=0.035), and TZV (p=0.005) differed significantly between the cancer and noncancer groups.
  • The results of the multivariate analysis showed that PSAD (p=0.022), PSAV (p<0.001), and TPV (p=0.037) had a statistically significant correlation with cancer detection.
  • CONCLUSIONS: PSAD, PSAV, and TPV are predictive factors of prostate cancer in patients with an initial diagnosis of ASAP of the prostate.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165194.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2991571
  • [Keywords] NOTNLM ; Diagnosis / Needle biopsy / Prostatic neoplasms
  •  go-up   go-down


42. Ploussard G, Plennevaux G, Allory Y, Salomon L, Azoulay S, Vordos D, Hoznek A, Abbou CC, de la Taille A: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World J Urol; 2009 Oct;27(5):587-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance.
  • PURPOSE: To evaluate the incidence of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in an initial 21-core extended biopsy scheme and to determine the prostate cancer detection rate in the repeated biopsy.
  • Incidences of cancer, ASAP and HGPIN were studied.
  • Cancer detection rate in the repeated 21-core extended biopsy for ASAP and HGPIN was reported and compared with those obtained on repeated biopsy for clinico-biological indications.
  • RESULTS: Incidences of HGPIN and ASAP were 1.7 and 1.1%, respectively.
  • Seven prostate cancers were found among the 17 re-biopsies for ASAP revealing a detection rate of 41.2% (p = 0.01).
  • CONCLUSION: Our report demonstrates the different risk profiles for HGPIN and ASAP in a 21-core extended biopsy scheme.
  • Repeated biopsy is warranted when ASAP is diagnosed because of a high risk of prostate cancer.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • HAL archives ouvertes. Full text from .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):828-32 [8606858.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Urology. 2005 Mar;65(3):538-42 [15780372.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Eur Urol. 2006 Oct;50(4):666-74 [16930809.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):430-5 [17412489.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1309-22 [17720304.001]
  • [Cites] Urology. 2000 Apr;55(4):553-9 [10736500.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):44-9 [11144903.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Urology. 2002 Nov;60(5):851-4 [12429314.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Urology. 2003 Jun;61(6):1181-6 [12809894.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):177-81 [15245810.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):260-6 [15368469.001]
  • (PMID = 19373471.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ HALMS423056; NLM/ PMC2825569
  •  go-up   go-down


43. Marstrand TT, Frellsen J, Moltke I, Thiim M, Valen E, Retelska D, Krogh A: Asap: a framework for over-representation statistics for transcription factor binding sites. PLoS One; 2008;3(2):e1623
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asap: a framework for over-representation statistics for transcription factor binding sites.
  • Furthermore it would be necessary to obtain several different software programs from various sources to make a well-founded choice.
  • METHODOLOGY: We introduce a software package, Asap, for fast searching with position weight matrices that include several standard methods for assessing over-representation.
  • An online server is available at http://servers.binf.ku.dk/asap/.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Genet. 2001;35:193-208 [11700282.001]
  • [Cites] Nucleic Acids Res. 2005;33(5):1445-53 [15760844.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):328-31 [11752328.001]
  • [Cites] Science. 2002 Mar 1;295(5560):1669-78 [11872831.001]
  • [Cites] Genome Res. 2002 May;12(5):832-9 [11997350.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):212-8 [12538241.001]
  • [Cites] Nucleic Acids Res. 2003 Mar 15;31(6):1753-64 [12626717.001]
  • [Cites] Nat Rev Genet. 2003 Apr;4(4):251-62 [12671656.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D91-4 [14681366.001]
  • [Cites] Cell. 2004 Feb 20;116(4):499-509 [14980218.001]
  • [Cites] Nat Rev Genet. 2004 Apr;5(4):276-87 [15131651.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W249-52 [15215389.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W253-6 [15215390.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):137-44 [15637633.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10 [16381825.001]
  • [Cites] Cell. 2006 Jan 13;124(1):207-19 [16413492.001]
  • [Cites] Genome Res. 2006 Mar;16(3):405-13 [16449500.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):396-406 [16537832.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):626-35 [16645617.001]
  • [Cites] Mol Biol Cell. 2007 May;18(5):1543-53 [17314394.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W245-52 [17576675.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D102-6 [18006571.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1113-22 [11751219.001]
  • (PMID = 18286180.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2229843
  •  go-up   go-down


44. Flannery RB Jr, Walker AP, Flannery GJ: Elderly patient assaults: empirical data from the Assaulted Staff Action Program (ASAP) with risk management implications for EMS personnel. Int J Emerg Ment Health; 2006;8(4):221-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elderly patient assaults: empirical data from the Assaulted Staff Action Program (ASAP) with risk management implications for EMS personnel.
  • Data on the assault characteristics of elderly patients are presented from a 15-year, retrospective, longitudinal study of the Assaulted Staff Action Program (ASAP).

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131768.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Vergeer M, Zhou R, Bots ML, Duivenvoorden R, Koglin J, Akdim F, Mitchel YB, Huijgen R, Sapre A, de Groot E, Sijbrands EJ, Pasternak RC, Gagné C, Marais AD, Ballantyne CM, Isaacsohn JL, Stalenhoef AF, Kastelein JJ: Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging; 2010 Jul;3(4):398-404
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies.
  • METHODS AND RESULTS: We retrospectively evaluated cIMT change, and prior statin treatment and postbaseline LDL-C change as predictors of cIMT change, in 1513 HeFH patients who were randomly assigned to the statin arms of the early ASAP and more recent RADIANCE 1, CAPTIVATE, and ENHANCE studies.
  • In the 3 recent studies combined, mean cIMT increased at only 33%of the rate of the simvastatin-treated patients in the ASAP study (0.014 mm/2 years [95% confidence interval, -0.0003-0.028] versus 0.041 mm/2 years [95% confidence interval, 0.020-0.061]; P<0.05).


46. Barrett KM, Ding YH, Wagner DP, Kallmes DF, Johnston KC, ASAP Investigators: Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke; 2009 Jul;40(7):2422-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy.
  • METHODS: The prospective Acute Stroke Accurate Prediction (ASAP) Study included a prespecified serial imaging subgroup who underwent DWI studies at baseline (<24 hours after symptom onset) and Day 5 (+/-2 days).
  • Univariate and multivariable regression analysis was performed to assess the relationship between change in DWI lesion volume and excellent neurological outcome (modified Rankin Scale 0, 1, and Barthel Index >or=95).
  • RESULTS: In total, 169 cases from the ASAP study had serial DWI scans with a measurable lesion at baseline, follow-up, or both.

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 1999 Nov;30(11):2347-54 [10548669.001]
  • [Cites] Stroke. 2007 Jun;38(6):1820-5 [17446421.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Sep;21(8):1434-40 [11003275.001]
  • [Cites] Stroke. 2000 Nov;31(11):2597-602 [11062281.001]
  • [Cites] Lancet. 2001 Jun 30;357(9274):2095-9 [11445104.001]
  • [Cites] Neurology. 2002 Nov 12;59(9):1381-7 [12427888.001]
  • [Cites] Stroke. 2004 Jan;35(1):158-62 [14684776.001]
  • [Cites] J Rehabil Res Dev. 2003 Jan-Feb;40(1):1-8 [15150715.001]
  • [Cites] Stroke. 1988 May;19(5):604-7 [3363593.001]
  • [Cites] Ann Neurol. 1995 Feb;37(2):231-41 [7847864.001]
  • [Cites] Stroke. 1995 Mar;26(3):392-8 [7886712.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Ann Neurol. 1997 May;41(5):581-9 [9153519.001]
  • [Cites] Stroke. 1998 Nov;29(11):2268-76 [9804633.001]
  • [Cites] Neurology. 1999 Jul 13;53(1):126-31 [10408548.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):568-78 [10514093.001]
  • [Cites] Md State Med J. 1965 Feb;14:61-5 [14258950.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1159-63 [16525124.001]
  • [Cites] Stroke. 2006 Dec;37(12):2951-6 [17082470.001]
  • [Cites] Stroke. 2000 Feb;31(2):448-55 [10657421.001]
  • (PMID = 19443798.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K24 NS052141; United States / NINDS NIH HHS / NS / K23 NS002168; United States / NINDS NIH HHS / NS / K23NS02168; United States / NINDS NIH HHS / NS / NS052141-04; United States / NINDS NIH HHS / NS / K24 NS052141-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS145284; NLM/ PMC2772139
  •  go-up   go-down


47. Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F: Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy"). Eur Urol; 2006 Oct;50(4):666-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy").
  • OBJECTIVE: To review atypical focus suspicious but not diagnostic of malignancy in needle biopsies of the prostate, also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy."
  • METHODS: A number of descriptive and somewhat confusing terms have been used to refer to a prostate tissue biopsy with small focus of atypical glands.
  • Based on MEDLINE database searches, all aspects, including the synonymous terms, of atypical focus suspicious but not diagnostic of malignancy were examined.
  • RESULTS: An average of 5% of needle biopsy pathology reports show a diagnosis of atypical focus suspicious for malignancy.
  • It may be composed of acini of small size, that is, smaller than normal ducts and acini, but may also include glands with a diameter similar to that of normal ducts and acini.
  • It encompasses a variety of lesions, including benign mimickers of cancer and small foci of carcinoma that, for a variety of reasons, cannot be accurately diagnosed.
  • The precise labelling of the initial biopsies is mandatory so that rebiopsy of patients with atypical foci can be directed in a more concentrated fashion into the region of the initial biopsy.
  • CONCLUSION: The presence of atypical focus suspicious but not diagnostic of malignancy in needle biopsies is an important predictor of cancer compared with biopsies from patients who lack this finding.
  • [MeSH-major] Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930809.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 67
  •  go-up   go-down


48. Ahyai SA, Isbarn H, Karakiewicz PI, Chun FK, Reichert M, Walz J, Steuber T, Jeldres C, Schlomm T, Heinzer H, Salomon G, Budäus L, Perrotte P, Huland H, Graefen M, Haese A: The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int; 2010 Mar;105(5):636-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of prostate cancer on saturation biopsy can be accurately predicted.
  • OBJECTIVE: To improve the ability of our previously reported saturation biopsy nomogram quantifying the risk of prostate cancer, as the use of office-based saturation biopsy has increased.
  • PATIENTS AND METHODS: Saturation biopsies of 540 men with one or more previously negative 6-12 core biopsies were used to develop a multivariable logistic regression model-based nomogram, predicting the probability of prostate cancer.
  • Candidate predictors were used in their original or stratified format, and consisted of age, total prostate-specific antigen (PSA) level, percentage free PSA (%fPSA), gland volume, findings on a digital rectal examination, cumulative number of previous biopsy sessions, presence of high-grade prostatic intraepithelial neoplasia on any previous biopsy, and presence of atypical small acinar proliferation (ASAP) on any previous biopsy.
  • RESULTS: Prostate cancer was diagnosed in 39.4% of saturation biopsies.
  • Age, total PSA, %fPSA, gland volume, number of previous biopsies, and presence of ASAP at any previous biopsy were independent predictors for prostate cancer (all P < 0.05).
  • The nomogram was 77.2% accurate and had a virtually perfect correlation between predicted and observed rates of prostate cancer.
  • CONCLUSIONS: We improved the accuracy of the saturation biopsy nomogram from 72% to 77%; it relies on three previously included variables, i.e. age, %fPSA and prostate volume, and on three previously excluded variables, i.e.
  • PSA, the number of previous biopsy sessions, and evidence of ASAP on previous biopsy.
  • [MeSH-major] Nomograms. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20149204.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


49. Trilla E, Morote J: [Prostate cancer. New diagnostic techniques. Current status of prostate biopsy]. Arch Esp Urol; 2006 Dec;59(10):945-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer. New diagnostic techniques. Current status of prostate biopsy].
  • OBJECTIVES: Ultrasound guided prostate biopsy is the only method to obtain the confirmation diagnosis of prostate cancer.
  • METHODS: Bibliographic review and critical analysis of the literature on prostate biopsy.
  • RESULTS/CONCLUSIONS: Published studies suggest extensive biopsy schemes increase detection rates in comparison to sextant biopsies, both first and successive biopsies, being necessary to sample the most lateral areas of the gland and the dorsal apex where the diagnostic yield is greater.
  • The indications for repeated biopsies after a negative one include high grade PIN and/or Atypical Small Acinar Proliferation (ASAP), persistent PSA elevation and/or total PSA doubling time increase.
  • [MeSH-major] Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy / methods. Biopsy / statistics & numerical data. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283708.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 55
  •  go-up   go-down


50. Koppelmans V, Schoevers R, van Wijk CG, Mulder W, Hornbach A, Barkhof E, Klaassen A, van Egmond M, van Venrooij J, Bijpost Y, Nusselder H, van Herrewaarden M, Maksimovic I, Achilles A, Dekker J: The Amsterdam Studies of Acute Psychiatry - II (ASAP-II): a comparative study of psychiatric intensive care units in the Netherlands. BMC Public Health; 2009;9:318

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Amsterdam Studies of Acute Psychiatry - II (ASAP-II): a comparative study of psychiatric intensive care units in the Netherlands.
  • METHOD/DESIGN: This paper describes the design of the Amsterdam Studies of Acute Psychiatry II (ASAP-II).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Soc Psychiatry. 2008 Jan;54(1):56-68 [18309759.001]
  • [Cites] Schizophr Res. 2000 Jun 16;43(2-3):117-23 [10858630.001]
  • [Cites] J Psychiatr Ment Health Nurs. 2008 Apr;15(3):195-202 [18307648.001]
  • [Cites] Psychol Assess. 2001 Sep;13(3):384-95 [11556275.001]
  • [Cites] Aust N Z J Psychiatry. 2001 Dec;35(6):841-5 [11990896.001]
  • [Cites] J Psychiatr Ment Health Nurs. 2002 Dec;9(6):689-95 [12472822.001]
  • [Cites] Br J Psychiatry. 2004 Feb;184:163-8 [14754830.001]
  • [Cites] Br J Psychiatry. 2004 Apr;184:293-8 [15056572.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):364-8 [15133592.001]
  • [Cites] Psychopharmacology (Berl). 1983;80(2):190-1 [6410449.001]
  • [Cites] Schizophr Bull. 1986;12(4):604-30 [3810066.001]
  • [Cites] Schizophr Bull. 1988;14(1):97-111 [3291097.001]
  • [Cites] Psychopharmacol Bull. 1989;25(2):168-73 [2574891.001]
  • [Cites] Gen Hosp Psychiatry. 1990 Sep;12(5):303-8 [2210347.001]
  • [Cites] Health Bull (Edinb). 1992 May;50(3):228-32 [1506191.001]
  • [Cites] Hosp Community Psychiatry. 1994 Jan;45(1):74-6 [8125468.001]
  • [Cites] Psychiatr Serv. 1997 Mar;48(3):395-7 [9057246.001]
  • [Cites] Psychiatr Serv. 1998 Jun;49(6):794-6 [9634159.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 Feb 11;150(6):319-22 [16503024.001]
  • [Cites] Psychiatr Prax. 2006 May;33(4):157-9 [16680625.001]
  • [Cites] BMC Psychiatry. 2008;8:35 [18479518.001]
  • (PMID = 19725981.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2753351
  •  go-up   go-down


51. Cai SX, Drewe J, Kemnitzer W: Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem; 2009 May;9(4):437-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents.
  • By applying a novel cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP) HTS assay, 4-aryl-4H-chromenes were identified as potent apoptosis inducers.
  • 4-Aryl-4H-chromenes were found to induce nuclear fragmentation and PARP cleavage, as well as to arrest cells at the G(2)/M stage followed by apoptosis as determined by the flow cytometry analysis assay in multiple human cell lines (e.g.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442043.001).
  • [ISSN] 1875-5992
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzopyrans; 0 / crolibulin; EC 3.4.22.- / Caspases
  • [Number-of-references] 65
  •  go-up   go-down


52. van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N, Beekman A, de Haan L, Dekker J: The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC Psychiatry; 2008;8:35
MedlinePlus Health Information. consumer health - Psychotic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area.
  • The number of studies that have examined this development and possible consequences in terms of optimizing health care delivery in emergency psychiatry is small and have a number of methodological shortcomings.
  • METHODS/DESIGN: This paper describes the design of the Amsterdam Study of Acute Psychiatry-I (ASAP-I).
  • The final aim is to find specific patient and health care factors that can be influenced by adjusting treatment programs in order to reduce the number of involuntary admissions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Psychiatry Suppl. 2000;(39):s41-8 [10945077.001]
  • [Cites] Psychiatr Q. 2005 Summer;76(2):139-65 [15884742.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(2):CD000011 [12076376.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2002 Jul;37(7):341-5 [12111027.001]
  • [Cites] J Clin Psychiatry. 2002 Oct;63(10):892-909 [12416599.001]
  • [Cites] Br J Psychiatry. 2003 Feb;182:105-16 [12562737.001]
  • [Cites] Br J Psychiatry. 2003 Feb;182:123-8 [12562739.001]
  • [Cites] Psychiatr Serv. 2003 Mar;54(3):351-5 [12610243.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2003 Sep;38(9):535-8 [14504739.001]
  • [Cites] J Clin Psychiatry. 2003;64 Suppl 16:24-33 [14680416.001]
  • [Cites] Br J Psychiatry. 2004 Feb;184:163-8 [14754830.001]
  • [Cites] Lancet. 2004 Jun 19;363(9426):2012-3 [15207948.001]
  • [Cites] Aust N Z J Psychiatry. 1976 Mar;10(1):27-32 [1065311.001]
  • [Cites] J Consult Clin Psychol. 1978 Jun;46(3):478-88 [670491.001]
  • [Cites] Psychol Med. 1983 Feb;13(1):177-83 [6133297.001]
  • [Cites] Psychol Med. 1985 Feb;15(1):189-94 [3991833.001]
  • [Cites] Arch Gen Psychiatry. 2005 Sep;62(9):975-83 [16143729.001]
  • [Cites] Am J Psychiatry. 2005 Oct;162(10):1785-804 [16199825.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 Feb 11;150(6):319-22 [16503024.001]
  • [Cites] Br J Psychiatry. 2006 Apr;188:386-91 [16582067.001]
  • [Cites] Psychiatr Prax. 2006 May;33(4):157-9 [16680625.001]
  • [Cites] Med Care. 1986 Jan;24(1):67-74 [3945130.001]
  • [Cites] Acta Psychiatr Scand. 1990 Jul;82(1):77-81 [2399824.001]
  • [Cites] J Pers Soc Psychol. 1990 Dec;59(6):1216-29 [2283588.001]
  • [Cites] Clin Neuropharmacol. 1991;14 Suppl 2:S33-44 [1684309.001]
  • [Cites] J Pers. 1992 Jun;60(2):175-215 [1635039.001]
  • [Cites] Acta Psychiatr Scand. 1992 Jul;86(1):32-7 [1414396.001]
  • [Cites] J Clin Psychiatry. 1993 Mar;54 Suppl:24-30 [8097195.001]
  • [Cites] Acta Psychiatr Scand. 1994 Jan;89(1):62-7 [7908156.001]
  • [Cites] Arch Gen Psychiatry. 1995 Mar;52(3):173-88 [7872841.001]
  • [Cites] Psychiatr Serv. 1996 May;47(5):487-96 [8740489.001]
  • [Cites] Lancet. 1996 Aug 10;348(9024):383-6 [8709739.001]
  • [Cites] Int Psychogeriatr. 1995 Fall;7(3):407-16 [8821348.001]
  • [Cites] Am J Psychiatry. 2005 Jan;162(1):12-24 [15625195.001]
  • [Cites] J Clin Pharm Ther. 2001 Oct;26(5):331-42 [11679023.001]
  • (PMID = 18479518.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2413231
  •  go-up   go-down


53. Chen VH, Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ: Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technol Cancer Res Treat; 2009 Apr;8(2):99-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection.
  • The 3-D transrectal ultrasound (TRUS)-guided prostate biopsy system is a novel device that allows precise needle placement in a template fashion.
  • We evaluate its utility for prostate cancer (PCa) detection.
  • A retrospective analysis was performed evaluating 68 prospective patients at the Duke Prostate Center who underwent a prostate biopsy using a 3-D TRUS-guided system.
  • After creation of a three-dimensional map of the prostate, a computer algorithm identified an ideal biopsy scheme based on the measured dimensions of the prostate.
  • The system then used a fixed template that allowed prostate biopsy at specific locations with the ability to target the same region of the prostate in the future if needed.
  • For all patients, a 12-core biopsy pattern was used to cover medial and lateral areas of the base, mid-gland, and apex.
  • In total, 68 patients underwent 3-D TRUS-guided prostate biopsies between April 2006 and November 2007 for prostate cancer detection.
  • The indication for prostate biopsy was PSA > or = 4.0 ng/ml in 47 (69%) patients, abnormal digital rectal examination (DRE) in 17 (25%), and atypia on previous biopsy in 4 (6%) patients.
  • Prostate cancer was detected in 18 patients (26.5%) and 7 (10.3%) had atypical small acinar proliferation (ASAP).
  • This study demonstrates that a 3-D TRUS-guided biopsy system translates to a more frequent detection of prostate cancer among patients undergoing an initial prostate biopsy than a subsequent one.
  • [MeSH-major] Imaging, Three-Dimensional / methods. Prostatic Neoplasms / pathology. Ultrasound, High-Intensity Focused, Transrectal / methods


54. Dhingra A, Folta KM: ASAP: amplification, sequencing & annotation of plastomes. BMC Genomics; 2005;6:176
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASAP: amplification, sequencing & annotation of plastomes.
  • Sequence analysis revealed large deletions in these species relative to tobacco plastome thus exhibiting the utility of this method for structural and comparative genomics studies.
  • [MeSH-major] DNA, Chloroplast / genetics. Plastids / genetics. Plastids / metabolism. Sequence Analysis, DNA / methods

  • COS Scholar Universe. author profiles.
  • SILVA. SILVA LSU Database .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plant Cell. 2005 Mar;17(3):665-75 [15705954.001]
  • [Cites] Methods Enzymol. 2005;395:348-84 [15865976.001]
  • [Cites] Trends Biotechnol. 2005 May;23(5):238-45 [15866001.001]
  • [Cites] Trends Plant Sci. 2005 May;10(5):203-9 [15882651.001]
  • [Cites] Gene. 2005 May 9;350(2):117-28 [15788152.001]
  • [Cites] BMC Plant Biol. 2005;5:12 [15985176.001]
  • [Cites] Plant Mol Biol. 2005 Sep;59(2):309-22 [16247559.001]
  • [Cites] Methods Mol Biol. 2006;323:245-62 [16739583.001]
  • [Cites] DNA Res. 1999 Oct 29;6(5):283-90 [10574454.001]
  • [Cites] DNA Res. 2000 Dec 31;7(6):323-30 [11214967.001]
  • [Cites] Plant Mol Biol. 2001 Feb;45(3):307-15 [11292076.001]
  • [Cites] Mol Genet Genomics. 2002 Jan;266(5):740-6 [11810247.001]
  • [Cites] Mol Biol Evol. 2002 Sep;19(9):1602-12 [12200487.001]
  • [Cites] DNA Res. 2003 Apr 30;10(2):59-65 [12755170.001]
  • [Cites] Mol Biol Evol. 2003 Sep;20(9):1499-505 [12832641.001]
  • [Cites] Mol Biol (Mosk). 2003 Sep-Oct;37(5):768-83 [14593913.001]
  • [Cites] Plant Physiol. 2004 Sep;136(1):2843-54 [15347789.001]
  • [Cites] Annu Rev Plant Biol. 2004;55:289-313 [15377222.001]
  • [Cites] DNA Res. 2004 Apr 30;11(2):93-9 [15449542.001]
  • [Cites] Trends Plant Sci. 2004 Oct;9(10):477-83 [15465682.001]
  • [Cites] DNA Res. 2004 Aug 31;11(4):247-61 [15500250.001]
  • [Cites] Annu Rev Genet. 1985;19:325-54 [3936406.001]
  • [Cites] Mol Gen Genet. 1989 Jun;217(2-3):185-94 [2770692.001]
  • [Cites] Nucleic Acids Res. 1991 Jul 25;19(14):4008 [1861999.001]
  • [Cites] Biotechniques. 1992 Mar;12(3):332-4 [1571138.001]
  • [Cites] J Mol Biol. 1995 Sep 1;251(5):614-28 [7666415.001]
  • [Cites] Curr Genet. 1997 May;31(5):419-29 [9162114.001]
  • [Cites] FEMS Microbiol Lett. 1999 May 15;174(2):247-50 [10339815.001]
  • [Cites] Genome Res. 1999 Sep;9(9):868-77 [10508846.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3252-5 [15180927.001]
  • [Cites] Plant Mol Biol. 2004 Sep;56(2):203-16 [15604738.001]
  • (PMID = 16336644.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Chloroplast; 0 / DNA, Plant
  • [Other-IDs] NLM/ PMC1318494
  •  go-up   go-down


55. Bittner N, Merrick GS, Andreini H, Taubenslag W, Allen ZA, Butler WM, Anderson RL, Adamovich E, Wallner KE: Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. Urology; 2009 Jul;74(1):171-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
  • OBJECTIVES: To evaluate the effect of prostate-specific antigen (PSA) velocity (PSAV) on prostate cancer diagnosis, Gleason score, tumor location, and cancer volume in men undergoing transperineal template-guided mapping biopsy (TTMB).
  • PSAV has been associated with greater Gleason scores and greater prostate cancer-specific mortality.
  • The inclusion criteria included a persistently elevated PSA level and/or diagnosis of atypical small acinar proliferation or high-grade prostatic intraepithelial neoplasia on previous biopsy.
  • The prostate gland was arbitrarily divided into 24 regions, and a median of 58 cores were obtained per patient.
  • The PSAV was evaluated as a predictor for prostate cancer diagnosis, Gleason score, tumor volume, and cancer location.
  • Prostate cancer was diagnosed in 97 patients (44.7%).
  • PSAV did not predict for prostate cancer diagnosis (P = .84), Gleason score (P = .78), the percentage of positive cores (P = .37), or tumor location.
  • CONCLUSIONS: Among patients with persistently elevated PSA levels despite previously negative biopsy findings, PSAV did not reliably predict for a diagnosis of prostate cancer nor did it correlate with prostate cancer grade, volume, or location using TTMB.
  • [MeSH-major] Biopsy, Needle / methods. Preoperative Care. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


56. Flannery RB Jr, Walker AP: Characteristics of patients in restraint: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications. Int J Emerg Ment Health; 2008;10(3):191-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients in restraint: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications.
  • This study compared restrained/nonrestrained subjects on the demographic, precipitant variables and added three clinical variables (past violence to others, personal victimization, and substance use disorder) to assess the possible predictive power of clinical variables.
  • [MeSH-major] Emergency Medical Services. Program Development. Psychotic Disorders / psychology. Restraint, Physical. Violence / psychology

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112931.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Flannery RB Jr, Laudani L, Levitre V, Walker AP: Precipitants of psychiatric patient assaults on staff: three-year empirical inquiry of the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2006;8(1):15-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precipitants of psychiatric patient assaults on staff: three-year empirical inquiry of the Assaulted Staff Action Program (ASAP).
  • Patient violence toward health care staff is a complex function of person x event x environment model.
  • Thirty-five years of research on the characteristics of patient assailants and staff victims has yielded no predictive markers and researchers are examining other possible components of the model.
  • Although research to date has been sparse, acute psychosis, excessive sensory stimulation, and staff restrictions on patient behaviors (denial of services, privileges, etc.) appear to be common precipitants.
  • No statistically significant interactions were obtained for patient / staff victim variables and these precipitants.
  • [MeSH-major] Health Personnel. Mental Disorders / psychology. Patients / psychology. Professional-Patient Relations. Program Development. Violence

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573249.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Flannery RB Jr, Flannery GJ, Walker AP: Time of psychiatric patient assaults: twenty-year analysis of the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2010;12(4):267-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time of psychiatric patient assaults: twenty-year analysis of the Assaulted Staff Action Program (ASAP).
  • Patient assaults on staff as acts of violence should also follow a temporal pattern.

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21870385.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Trimpin S, Wijerathne K, McEwen CN: Rapid methods of polymer and polymer additives identification: multi-sample solvent-free MALDI, pyrolysis at atmospheric pressure, and atmospheric solids analysis probe mass spectrometry. Anal Chim Acta; 2009 Nov 3;654(1):20-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid methods of polymer and polymer additives identification: multi-sample solvent-free MALDI, pyrolysis at atmospheric pressure, and atmospheric solids analysis probe mass spectrometry.
  • Numerous analytical methods are available to characterize various chemical aspects of polymers including methods interfaced with mass spectrometry (MS) such as pyrolysis (Py), gas chromatography (GC), liquid chromatography (LC), and thermogravimetric analysis (TGA).
  • Here we discuss three MS methods for rapid analysis of polymers; multi-sample MALDI MS which allows rapid analysis of low molecular weight polymers, atmospheric pressure (AP) solids analysis probe MS for direct ambient additives analysis, and APPy MS for polymer identification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850163.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


60. McFarland BH, Gabriel RM, Bigelow DA, Walker RD: Organization and financing of alcohol and substance abuse programs for American Indians and Alaska Natives. Am J Public Health; 2006 Aug;96(8):1469-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organization and financing of alcohol and substance abuse programs for American Indians and Alaska Natives.
  • OBJECTIVES: Although American Indians and Alaska Natives have high rates of substance abuse, few data about treatment services for this population are available.
  • METHODS: Using data from the Indian Health Service (IHS), the Substance Abuse and Mental Health Services Administration, the National Institute on Alcohol Abuse and Alcoholism, the Henry J.
  • Kaiser Family Foundation, and the Census Bureau, we estimated the number of American Indians served by substance abuse treatment programs that apparently are unaffiliated with either the IHS or tribal governments.
  • RESULTS: Half of the American Indians and Alaska Natives treated for substance abuse were served by programs (chiefly in urban areas) apparently unaffiliated with the IHS or tribal governments.
  • IHS substance abuse expenditures were roughly what we expected.
  • Medicaid participation by tribal programs was not universal.
  • CONCLUSIONS: Many Native people with substance abuse problems are served by programs unaffiliated with the IHS.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):223-34 [15194200.001]
  • [Cites] Am J Public Health. 2004 Jan;94(1):53-9 [14713698.001]
  • [Cites] Am J Public Health. 2000 Mar;90(3):344-51 [10705850.001]
  • [Cites] Am J Med Qual. 2000 Jul-Aug;15(4):148-56 [10948787.001]
  • [Cites] J Addict Dis. 2000;19(3):13-34 [11076117.001]
  • [Cites] Am J Public Health. 2000 Nov;90(11):1720-3 [11076238.001]
  • [Cites] Psychiatr Serv. 2001 Jan;52(1):68-74 [11141531.001]
  • [Cites] J Psychoactive Drugs. 2002 Jan-Mar;34(1):1-6 [12003107.001]
  • [Cites] Psychiatr Serv. 2002 Jul;53(7):802 [12096160.001]
  • [Cites] J Addict Dis. 2003;22(2):15-29 [12703666.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Aug;27(8):1333-6 [12966333.001]
  • [Cites] J Stud Alcohol Suppl. 1981 Jan;9:143-58 [7012345.001]
  • [Cites] Public Health Rep. 1988 Nov-Dec;103(6):611-20 [3141955.001]
  • [Cites] J Subst Abuse Treat. 1992;9(2):93-102 [1512807.001]
  • [Cites] West J Med. 1992 Sep;157(3):281-5 [1413770.001]
  • [Cites] Addiction. 1993 Mar;88(3):315-35 [8461850.001]
  • [Cites] Am J Health Promot. 1995 Mar-Apr;9(4):288-99 [10150732.001]
  • [Cites] J Subst Abuse. 1995;7(1):1-8 [7655307.001]
  • [Cites] J Subst Abuse. 1995;7(1):135-50 [7655309.001]
  • [Cites] J Subst Abuse. 1995;7(1):27-42 [7655310.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1995;6(3):31-45 [8555352.001]
  • [Cites] J Stud Alcohol. 1995 Nov;56(6):597-610 [8558890.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):237-40 [8551886.001]
  • [Cites] J Clin Epidemiol. 1996 Apr;49(4):473-82 [8622000.001]
  • [Cites] JAMA. 1996 Jun 19;275(23):1786-8 [8642709.001]
  • [Cites] J Stud Alcohol. 1996 May;57(3):229-43 [8709580.001]
  • [Cites] J Stud Alcohol. 1996 Jan;57(1):65-72 [8747503.001]
  • [Cites] JAMA. 1997 Apr 2;277(13):1039-45 [9091691.001]
  • [Cites] JAMA. 1997 Apr 2;277(13):1079-80 [9091699.001]
  • [Cites] Adm Policy Ment Health. 1997 Jul;24(6):459-74 [9385711.001]
  • [Cites] Med Care Res Rev. 1997 Dec;54(4):490-507 [9437178.001]
  • [Cites] N Engl J Med. 1998 Feb 26;338(9):592-602 [9475768.001]
  • [Cites] Am J Public Health. 1998 Feb;88(2):193-5 [9491006.001]
  • [Cites] J Behav Health Serv Res. 1998 Nov;25(4):377-96 [9796161.001]
  • [Cites] Subst Use Misuse. 1998 Nov;33(13):2605-46 [9818991.001]
  • [Cites] J Subst Abuse Treat. 1999 Jan;16(1):71-80 [9888124.001]
  • [Cites] Am J Public Health. 2005 May;95(5):766-8 [15855449.001]
  • [Cites] J Behav Health Serv Res. 2000 Feb;27(1):17-28 [10695238.001]
  • (PMID = 16809606.001).
  • [ISSN] 1541-0048
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R21 AA014050; United States / NIAAA NIH HHS / AA / 1R21 AA014050; United States / CSAP SAMHSA HHS / SP / 1U79 SP10346
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1522117
  •  go-up   go-down


61. Flannery RB Jr, Farley E, Rego S, Walker AP: Characteristics of staff victims of pschiatric patient assaults: 15-year analysis of the Assaulted Staff Action Program (ASAP). Psychiatr Q; 2007 Mar;78(1):25-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of staff victims of pschiatric patient assaults: 15-year analysis of the Assaulted Staff Action Program (ASAP).
  • Psychiatric patient assaults on staff victims are a worldwide occupational hazard.
  • This paper reports on a 15-year study of the characteristics of staff victims of patient assaults and a crisis intervention procedure to ameliorate the aftermath of theses incidents.
  • The validity of the study's findings are noted and the implications for enhanced risk management training and staff victim crisis intervention procedures are discussed.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Harv Rev Psychiatry. 2000 Nov;8(5):261-70 [11118235.001]
  • [Cites] Psychol Sci Public Interest. 2003 Nov;4(2):45-79 [26151755.001]
  • [Cites] J Interpers Violence. 2004 Aug;19(8):857-74 [15231026.001]
  • [Cites] J Ment Health Adm. 1994 Winter;21(1):24-31 [10131885.001]
  • [Cites] Online J Issues Nurs. 2004 Sep 30;9(3):7 [15482093.001]
  • [Cites] Psychiatr Q. 2006 Fall;77(3):231-8 [16955369.001]
  • [Cites] J Clin Nurs. 2004 Jan;13(1):3-10 [14687287.001]
  • [Cites] AAOHN J. 1996 Dec;44(12):575-80 [9043223.001]
  • [Cites] Adv Mind Body Med. 2001 Summer;17(3):163-8 [11572842.001]
  • [Cites] Annu Rev Psychol. 1997;48:449-80 [9046566.001]
  • [Cites] Psychiatr Q. 2001 Fall;72(3):237-48 [11467157.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2004 Jan-Feb;19(1):35-8 [15002343.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2001 May-Jun;16(3):153-6 [11398563.001]
  • [Cites] Hosp Community Psychiatry. 1991 Jun;42(6):585-90 [1864567.001]
  • [Cites] J Psychosoc Nurs Ment Health Serv. 1991 May;29(5):21-6 [2066912.001]
  • [Cites] Hosp Community Psychiatry. 1981 Jul;32(7):497-8 [7239475.001]
  • (PMID = 17102934.001).
  • [ISSN] 0033-2720
  • [Journal-full-title] The Psychiatric quarterly
  • [ISO-abbreviation] Psychiatr Q
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Flannery RB Jr, Walker AP: Repetitively assaultive psychiatric patients: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with implications for emergency services. Int J Emerg Ment Health; 2008;10(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repetitively assaultive psychiatric patients: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with implications for emergency services.
  • Embedded within these patient assailants is a small group of repeat offenders who present a serious increased risk for assault.
  • The risk of assault was greatly increased if these patients had histories of violence toward others, personal victimization, and substance use disorder.

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546755.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Flannery RB Jr, Walker AP: Characteristics of four types of patient assaults: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications. Int J Emerg Ment Health; 2008;10(3):177-84
MedlinePlus Health Information. consumer health - Emergency Medical Services.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of four types of patient assaults: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications.
  • However six studies that have reported physical assault, sexual assault, nonverbal intimidation, and verbal threats as separate categories have reported significant patient/staff victim differences in characteristics by category.
  • [MeSH-major] Emergency Medical Services / statistics & numerical data. Professional-Patient Relations. Program Development. Violence / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112929.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Jiwa A, Kelly L, Pierre-Hansen N: Healing the community to heal the individual: literature review of aboriginal community-based alcohol and substance abuse programs. Can Fam Physician; 2008 Jul;54(7):1000-1000.e7
MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing the community to heal the individual: literature review of aboriginal community-based alcohol and substance abuse programs.
  • OBJECTIVE: To understand the development of culturally based and community-based alcohol and substance abuse treatment programs for aboriginal patients in an international context.
  • MeSH headings included the following: Indians, North American, Pacific ancestry group, aboriginal, substance-related disorders, alcoholism, addictive behaviour, community health service, and indigenous health.
  • The search produced 150 articles, 34 of which were relevant; most of the literature comprised opinion pieces and program descriptions (level III evidence).
  • MAIN MESSAGE: Substance abuse in some aboriginal communities is a complex problem requiring culturally appropriate, multidimensional approaches.
  • One promising perspective supports community-based programs or community mobile treatment.
  • These programs ideally cover prevention, harm reduction, treatment, and aftercare.
  • CONCLUSION: Community-based addictions programs are appropriate alternatives to treatment at distant residential addictions facilities.
  • The key components of success appear to be strong leadership in this area; strong community-member engagement; funding for programming and organizing; and the ability to develop infrastructure for longterm program sustainability.
  • Programs require increased documentation of their inroads in this developing field.
  • [MeSH-major] Alcoholism / ethnology. Alcoholism / rehabilitation. Substance-Related Disorders / ethnology. Substance-Related Disorders / rehabilitation

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2000 Jan;95(1):11-22 [10723822.001]
  • [Cites] Am J Med Qual. 2000 Jul-Aug;15(4):148-56 [10948787.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 2001;10(2):85-98 [11698985.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):15-25 [12733754.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):27-31 [12733755.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):71-7 [12733761.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):85-8 [12733763.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):89-96 [12733764.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Aug;27(8):1356-60 [12966339.001]
  • [Cites] Am J Community Psychol. 2004 Jun;33(3-4):263-73 [15212184.001]
  • [Cites] Int J Addict. 1985 Nov-Dec;20(11-12):1707-26 [3833806.001]
  • [Cites] J Stud Alcohol. 1986 May;47(3):187-95 [3724152.001]
  • [Cites] Can J Public Health. 1988 Nov-Dec;79(6):424-9 [3233567.001]
  • [Cites] Community Health Stud. 1989;13(1):14-22 [2736901.001]
  • [Cites] R I Med J. 1991 Jun;74(6):281-6 [1887191.001]
  • [Cites] J Addict Dis. 1992;11(3):63-80 [1627667.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;4(3):105-11; discussion 126-32 [1504169.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;4(3):5-59; discussion 71-5, 95-100 [1504172.001]
  • [Cites] Int J Soc Psychiatry. 1992 Autumn;38(3):208-14 [1428664.001]
  • [Cites] Arctic Med Res. 1991;Suppl:271-5 [1365127.001]
  • [Cites] Aust J Public Health. 1995 Dec;19(6):567-72 [8616196.001]
  • [Cites] J Subst Abuse Treat. 1996 Jan-Feb;13(1):23-31 [8699539.001]
  • [Cites] J Subst Abuse Treat. 1996 May-Jun;13(3):265-71 [9017570.001]
  • [Cites] Subst Use Misuse. 1998 Nov;33(13):2605-46 [9818991.001]
  • [Cites] N Z Med J. 2006;119(1228):U1809 [16462919.001]
  • [CommentIn] Can Fam Physician. 2008 Jul;54(7):961, 963 [18625806.001]
  • (PMID = 18625824.001).
  • [ISSN] 1715-5258
  • [Journal-full-title] Canadian family physician Médecin de famille canadien
  • [ISO-abbreviation] Can Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC2464791
  •  go-up   go-down


65. Flannery RB Jr, White DL, Flannery GJ, Walker AP: Time of psychiatric patient assaults: fifteen-year analysis of the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2007;9(2):89-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time of psychiatric patient assaults: fifteen-year analysis of the Assaulted Staff Action Program (ASAP).
  • This study reviews this literature and presents the temporal findings of a fifteen-year study of patient assaults on staff in health care settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725077.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


66. Flannery RB Jr, Marks L, Laudani L, Walker AP: Psychiatric patient assault and staff victim gender: fifteen-year analysis of the Assaulted Staff Action Program (ASAP). Psychiatr Q; 2007 Jun;78(2):83-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric patient assault and staff victim gender: fifteen-year analysis of the Assaulted Staff Action Program (ASAP).
  • Extensive, largely cross-sectional research has documented the continued occurrence of patient assaults on male and female staff.
  • Different studies report either male or female staff to be at highest risk.
  • In these latter studies both male and female staff were at high risk for same gender assaults.
  • Male and female staff were at increased risk from same gender assaults over time in both inpatient and community settings.
  • [MeSH-minor] Adult. Aggression / psychology. Community Mental Health Services / statistics & numerical data. Cost-Benefit Analysis. Female. Hospitalization / statistics & numerical data. Humans. Longitudinal Studies. Male. Medical Staff, Hospital / statistics & numerical data. Personnel, Hospital / statistics & numerical data. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Management / economics. Risk Management / methods. Risk Management / organization & administration. Sex Distribution. Sex Factors

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345159.001).
  • [ISSN] 0033-2720
  • [Journal-full-title] The Psychiatric quarterly
  • [ISO-abbreviation] Psychiatr Q
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Flannery RB Jr, Hanson MA, Corrigan M, Walker AP: Past violence, substance use, and precipitants to psychiatric patient assaults: eleven-year analysis of the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2006;8(3):157-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Past violence, substance use, and precipitants to psychiatric patient assaults: eleven-year analysis of the Assaulted Staff Action Program (ASAP).
  • This study examined three commonly present, patient clinical variables (past violence toward others, personal victimization, and substance use disorder) singly and in combinations as potential predictor variables.
  • An additional subset analysis of patient precipitants was added to ascertain whether precipitant data would add further predictive power The combinations of past violence toward others and personal victimization with and without substances use disorder during an eleven-year period were associated with 61% of the subsequent assaults.
  • [MeSH-minor] Adolescent. Adult. Child. Community Mental Health Centers. Crime Victims / psychology. Female. Health Services Accessibility. Hospitals, State. Humans. Male. Massachusetts / epidemiology. Probability. Risk Factors. Sensory Thresholds. Substance-Related Disorders / complications. Substance-Related Disorders / psychology

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944788.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Hamilton-Reeves JM, Rebello SA, Thomas W, Kurzer MS, Slaton JW: Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer; 2008;60(1):7-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer.
  • Fifty-eight men at high risk of prostate cancer or with low-grade prostate cancer were randomly assigned to consume 1 of 3 protein isolates containing 40 g protein:.
  • 2) alcohol-washed soy protein (SPI-, <6 mg isoflavones/d); or 3) milk protein (MPI).
  • Proliferating cell nuclear antigen (PCNA), epidermal growth factor receptor, B-cell non-Hodgkin lymphoma-2 (Bcl-2), and Bcl-2-associated X protein (Bax) were assessed in baseline and ending prostate biopsy cores.
  • Serum collected at 0, 3, and 6 mo was analyzed for total and free prostate specific antigen (PSA).
  • Consumption of SPI+ did not alter any of the prostate cancer tumor markers.
  • Interestingly, a lower rate of prostate cancer developed in the soy groups compared to the milk group (P = 0.01).
  • These data suggest that 6-mo SPI+ consumption does not alter prostate tissue biomarkers, SPI- consumption exerts mixed effects, and less prostate cancer is detected after 6 mo of soy consumption regardless of isoflavone content.
  • [MeSH-major] Isoflavones / administration & dosage. Milk Proteins / administration & dosage. Prostatic Neoplasms / metabolism. Soybean Proteins / administration & dosage
  • [MeSH-minor] Aged. Animals. Biomarkers / analysis. Biomarkers / blood. Dietary Proteins / administration & dosage. Humans. Male. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Prostate-Specific Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Time Factors. bcl-2-Associated X Protein / metabolism


69. Leite KR, Mitteldorf CA, Camara-Lopes LH: Repeat prostate biopsies following diagnoses of prostate intraepithelial neoplasia and atypical small gland proliferation. Int Braz J Urol; 2005 Mar-Apr;31(2):131-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat prostate biopsies following diagnoses of prostate intraepithelial neoplasia and atypical small gland proliferation.
  • OBJECTIVE: To assess the incidence of diagnosis of high-grade intraepithelial neoplasia or prostate intraepithelial neoplasia (PIN), and atypical small gland proliferation (ASAP) at a uropathology reference center.
  • MATERIALS AND METHODS: Diagnoses of PIN, ASAP or PIN + ASAP established between January 1, 2001 and December 31, 2003 were searched in our database.
  • RESULTS: Of 1420 biopsies, ASAP was diagnosed in 26 (1.8%) patients, PIN in 142 (10%) and PIN + ASAP in 40 (2.8%).
  • Repeat biopsies were performed in 98 patients, 16 (61.5%) with ASAP, 53 (37.3%) with PIN and 29 (72.5%) with PIN + ASAP.
  • Carcinoma was diagnosed in 7 cases (43.8%) following a diagnosis of ASAP, 12 (41.4%) of PIN + ASAP and 7 (13.2%) of PIN.
  • CONCLUSION: Despite explicit recommendations of repeat biopsy on pathology reports and the high incidence of adenocarcinoma on repeat biopsy, re-intervention rates following a diagnosis of PIN, ASAP, PIN + ASAP are low in our setting.
  • The diagnosis that most frequently led to repeat biopsy was PIN + ASAP.
  • Adenocarcinoma was most often diagnosed after the initial diagnosis of ASAP.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy / utilization. Practice Patterns, Physicians' / statistics & numerical data. Prostatic Diseases / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15877832.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


70. Brimo F, Vollmer RT, Corcos J, Humphrey PA, Bismar TA: Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia. Am J Clin Pathol; 2007 Oct;128(4):648-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia.
  • We studied the relationships between the outcome in the last follow-up prostate biopsy specimen and serum prostate-specific antigen (PSA), prostatic intraepithelial neoplasia (PIN), and atypical small acinar proliferations (ASAPs) at the occasion of the initial biopsy in 244 cases in which the initial specimen was negative for tumor and at least 1 follow-up biopsy was done.
  • PSA levels and ASAPs were significantly associated with cancer in the follow-up biopsy specimen (<P < .005; logistic regression analysis); however, the presence of PIN in the initial biopsy specimen did not relate to cancer in the follow-up specimen (P > .1).
  • Thus, the probability that a follow-up biopsy demonstrates cancer depends on PSA and ASAPs, and even when ASAPs are present, serum PSA exerts an influence.
  • For example, low PSA values, 5 ng/mL (5 mug/L) or less, are associated with low probabilities of a positive follow-up biopsy result, even when ASAPs were present in the first biopsy specimen.
  • For higher PSA values, the presence of ASAPs dramatically increases the probability of a positive follow-up biopsy result compared with cases with no atypia or PIN in the first biopsy specimen.
  • [MeSH-major] Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875517.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


71. May DE, Kratochvil CJ, Puumala SE, Silva SG, Rezac AJ, Hallin MJ, Reinecke MA, Vitiello B, Weller EB, Pathak S, Simons AD, March JS: A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry; 2007 May;46(5):573-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The use of adjunct services for attrition prevention (ASAP) is described for adolescents (ages 12-17 years) during the 12-week acute treatment in TADS, from 2000 to 2003.
  • RESULTS: Of 439 enrolled participants, 17.8% (n = 78) used ASAP primarily for suicidality or worsening of depression.
  • ASAP use did not differ between treatments (p =.97) and typically occurred early in treatment.
  • At the end of the 12 weeks, 37.2% of participants using ASAP remained in their assigned treatment, although 80.8% continued participating in assessments.
  • ASAP was associated with, at baseline, a higher severity of depression (p <.01), substance use (p <.01), and precontemplation level of change (p <.02).
  • CONCLUSIONS: ASAP may be useful to retain adolescent participants and as a safety intervention in placebo-controlled trials.
  • In clinical practice ASAP-like procedures may be useful to encourage adherence in patients engaging in long-term treatment.

  • Genetic Alliance. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450048.001).
  • [ISSN] 0890-8567
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006286
  • [Grant] United States / NIMH NIH HHS / MH / N01 MH80008
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


72. Brewer BR, Pradhan S, Carvell G, Delitto A: Application of modified regression techniques to a quantitative assessment for the motor signs of Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng; 2009 Dec;17(6):568-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have used commercially available sensors to create a protocol called Advanced Sensing for Assessment of Parkinson's disease (ASAP) to obtain a quantitative and reliable measure of motor impairment in early to moderate PD.
  • The ASAP protocol measures grip force as an individual tracks a sinusoidal or pseudorandom target force under three conditions of increasing cognitive load.
  • Thirty individuals with PD have completed the ASAP protocol.
  • The ASAP data for 26 of these individuals were summarized in terms of 36 variables, and modified regression techniques were used to predict an individual's score on the Unified Parkinson Disease Rating Scale based on ASAP data.
  • These results demonstrate that the ASAP protocol can measure differences for individuals who are clinically different.
  • This indicates that the ASAP protocol may be able to measure changes with time in the motor signs of an individual with PD.
  • [MeSH-minor] Data Interpretation, Statistical. Humans. Regression Analysis. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Movement Disorders.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884100.001).
  • [ISSN] 1558-0210
  • [Journal-full-title] IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society
  • [ISO-abbreviation] IEEE Trans Neural Syst Rehabil Eng
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P30 AG024827
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS538314; NLM/ PMC4894031
  •  go-up   go-down


73. Zilberman MV, Karpawich PP: Alternate site atrial pacing in the young: conventional echocardiography and tissue Doppler analysis of the effects on atrial function and ventricular filling. Pacing Clin Electrophysiol; 2007 Jun;30(6):755-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate site atrial pacing in the young: conventional echocardiography and tissue Doppler analysis of the effects on atrial function and ventricular filling.
  • BACKGROUND: Although the right atrial appendage (RAA) is typically used for atrial pacing lead implant, recent studies have shown benefits of alternate site atrial pacing (ASAP) in the elderly.
  • METHODS: To investigate effects of ASAP on cardiac function and atrioventricular mechanical interactions in the young, 26 subjects (ages 10 to 23 years) with normal cardiac anatomy, function, and atrioventricular node conduction underwent echocardiography during electrophysiology studies while in sinus rhythm (NSR), and with temporary pacing from high right atrium (HRA), RAA, mid septal right atrium approximating Bachmann's bundle (BB), and left atrium (LA) via the distal coronary sinus (CS).
  • RESULTS: The total and systolic LA ejection fractions were higher during the NSR compared to all ASAP.
  • Mitral inflow velocities changed significantly with ASAP.
  • There were significant changes in late diastolic tissue Doppler velocities during ASAP compared to NSR.
  • The MPI during ASAP differed from those during the NSR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17547608.001).
  • [ISSN] 0147-8389
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Domzalski T, Cook C, Attarian DE, Kelley SS, Bolognesi MP, Vail TP: Activity scale for arthroplasty patients after total hip arthroplasty. J Arthroplasty; 2010 Jan;25(1):152-7
MedlinePlus Health Information. consumer health - Hip Replacement.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the Activity Scale for Arthroplasty Patients (ASAP) is to develop and validate a self-report questionnaire that demonstrated discrimination of functional gains, low burden, appropriate concurrent validity, and was not limited by ceiling effects.
  • We identified 128 high-functioning hip arthroplasty patients from our database who completed a 25-item ASAP and Lower Extremity Functional Scale questionnaires and a set of anchor questions.
  • Factor analysis identified 10 items associated with 2 distinct factors:.
  • These 10 items were retained and were identified as the ASAP.
  • The ASAP may be useful in high-level hip arthroplasty patients where other scales fail to capture activities secondary to ceiling effects.


75. Baker DP, Krokos KJ: Development and validation of Aviation Causal Contributors for Error Reporting Systems (ACCERS). Hum Factors; 2007 Apr;49(2):185-99
MedlinePlus Health Information. consumer health - Safety.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This investigation sought to develop a reliable and valid classification system for identifying and classifying the underlying causes of pilot errors reported under the Aviation Safety Action Program (ASAP).
  • BACKGROUND: ASAP is a voluntary safety program that air carriers may establish to study pilot and crew performance on the line.
  • In ASAP programs, similar to the Aviation Safety Reporting System, pilots self-report incidents by filing a short text description of the event.
  • The reliability and utility of ACCERS was then tested in studies 3a and 3b by having pilots independently classify the primary and secondary causes of ASAP reports.
  • CONCLUSIONS: ACCERS appears to be a useful system for studying human error captured under pilot ASAP reports.
  • Future work should focus on how ACCERS is organized and whether it can be used or modified to classify human error in ASAP programs for other aviation-related job categories such as dispatchers.
  • [MeSH-major] Accidents, Aviation / classification. Aviation / standards. Risk Management / methods. Safety. Task Performance and Analysis
  • [MeSH-minor] Causality. Classification / methods. Factor Analysis, Statistical. Forms and Records Control / methods. Humans. Reproducibility of Results. Research Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447662.001).
  • [ISSN] 0018-7208
  • [Journal-full-title] Human factors
  • [ISO-abbreviation] Hum Factors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


76. Dai W, Dong J, Fang T, Uemura T: Stimulation of osteogenic activity in mesenchymal stem cells by FK506. J Biomed Mater Res A; 2008 Jul;86(1):235-43
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MSCs were cultured in alpha-MEM containing either (1) L-ascorbic acid-2-phosphate (AsAP) and beta-glycerophosphate (beta-GP) as a control;.
  • (2) AsAP and beta-GP plus FK506;.
  • (3) AsAP and beta-GP plus Dex; or (4) AsAP and beta-GP plus FK506 and Dex.
  • Sixteen days later, cells were harvested for analysis.
  • The best results were achieved with alpha-MEM containing 0.25 mM AsAP, 10 mM beta-GP, 10 nM Dex, and 50 nM FK506.
  • [MeSH-minor] Alkaline Phosphatase / metabolism. Animals. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Calcium / chemistry. Calcium / metabolism. Cell Proliferation. Male. Microscopy, Electron, Scanning. Osteocalcin / chemistry. Osteogenesis. Rats. Rats, Inbred F344

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 18080300.001).
  • [ISSN] 1552-4965
  • [Journal-full-title] Journal of biomedical materials research. Part A
  • [ISO-abbreviation] J Biomed Mater Res A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase; SY7Q814VUP / Calcium; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


77. Cautin RL: The Founding of the Association for Psychological Science: Part 2. The Tipping Point and Early Years. Perspect Psychol Sci; 2009 May;4(3):224-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1987, the Assembly for Scientific and Applied Psychologists (ASAP) formed to encourage APA reorganization, and in early 1988, the APA Council approved a reorganization plan; that plan was, however, rejected by the membership.
  • In August 1988, the ASAP became the APS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Association for Psychological Science.
  • (PMID = 26158960.001).
  • [ISSN] 1745-6916
  • [Journal-full-title] Perspectives on psychological science : a journal of the Association for Psychological Science
  • [ISO-abbreviation] Perspect Psychol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Messieha Z, Ananda RC, Hoffman I, Hoffman W: Five year outcomes study of dental rehabilitation conducted under general anesthesia for special needs patients. Anesth Prog; 2007;54(4):170-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the safety of general anesthesia for dental treatment of special needs patients as it related to American Society of Anesthesiology Physical Status (ASAPS) classification, procedure, and other factors.
  • All records were evaluated by an independent evaluator who tabulated the patients' age, gender, ASAPS, and duration of procedure.
  • N = 363, age mean = 46.93 +/- 16.835 years, age median = 48 years, male patients = 180, female patients = 183, ASAPS I =183, ASAPS II = 127, ASAPS III = 53, duration of surgery mean = 140.631 +/- 23.104 minutes, duration of surgery median time = 142.000 minutes, and number of complications = 2.
  • One complication resulted in an ASAPS I 16-year-old boy, which was airway related, and a second was an ASAPS III 22-year-old woman, which was surgically related.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Nov 27;354(9193):1864-6 [10584723.001]
  • [Cites] Spec Care Dentist. 2006 Jan-Feb;26(1):25-9 [16703931.001]
  • [Cites] Eur J Anaesthesiol. 2000 Apr;17(4):230-5 [10866005.001]
  • [Cites] Spec Care Dentist. 2000 May-Jun;20(3):81-92 [11203886.001]
  • [Cites] Anaesthesia. 2001 Aug;56(8):745-55 [11493237.001]
  • [Cites] Paediatr Anaesth. 2001 Nov;11(6):637-41 [11696137.001]
  • [Cites] Drugs Aging. 2002;19(6):429-51 [12149050.001]
  • [Cites] Dent Clin North Am. 1987 Jan;31(1):131-8 [3468008.001]
  • [Cites] Anesth Pain Control Dent. 1992 Winter;1(1):46-8 [1392682.001]
  • [Cites] Anaesthesia. 1997 May;52(5):477-82 [9165968.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):646-51 [9195616.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):857-61 [9525362.001]
  • [Cites] Dent Clin North Am. 1999 Apr;43(2):301-19, vi [10331145.001]
  • [Cites] Minerva Anestesiol. 1999 Jul-Aug;65(7-8):499-505 [10479836.001]
  • [Cites] Drugs. 1999 Sep;58(3):453-67 [10493273.001]
  • [Cites] Anaesthesia. 2000 Jan;55(1):32-41 [10594431.001]
  • (PMID = 18085838.001).
  • [ISSN] 0003-3006
  • [Journal-full-title] Anesthesia progress
  • [ISO-abbreviation] Anesth Prog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2213248
  •  go-up   go-down


79. Lloyd JA, Harron AF, McEwen CN: Combination atmospheric pressure solids analysis probe and desorption electrospray ionization mass spectrometry ion source. Anal Chem; 2009 Nov 1;81(21):9158-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination atmospheric pressure solids analysis probe and desorption electrospray ionization mass spectrometry ion source.
  • The atmospheric solids probe analysis (ASAP) probe was investigated as a means for conducting desorption electrospray ionization (DESI) using a commercially available ion source.
  • Solid and liquid samples as well as a raw urine sample were placed on individual melting point tubes and were inserted into either a heated gas stream for ASAP analysis or a charged solvent spray for DESI-like experiments.
  • The configuration of the ion source also allowed rapid switching (approximately 1 min) between ASAP, electrospray ionization (ESI), and DESI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19807111.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Martens MB, Keller JH: Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Mod Pathol; 2006 Feb;19(2):287-90
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
  • A total of 43 cases of postirradiation prostate cores were assessed in an attempt to determine if routine use of alpha-methylacyl-CoA racemase (AMACR) in conjunction with high-molecular weight cytokeratin (HMWCK) would increase the recognition of carcinoma in postirradiation prostate biopsies.
  • We concluded that in most cases the addition of AMACR in conjunction with HMWCK does not increase the recognition of prostatic adenocarcinoma, however it is supportive in nature.
  • In one case the use of AMACR highlighted the extent of the adenocarcinoma which otherwise would have been designated as atypical small acinar proliferation (ASAP).
  • Further evaluation is required to assess the significance of a diagnosis of atypical small acinar proliferation in postirradiation prostate biopsies.
  • [MeSH-major] Keratins / analysis. Prostate / chemistry. Prostatic Neoplasms / metabolism. Racemases and Epimerases / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341144.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


81. James GA, Lu ZL, VanMeter JW, Sathian K, Hu XP, Butler AJ: Changes in resting state effective connectivity in the motor network following rehabilitation of upper extremity poststroke paresis. Top Stroke Rehabil; 2009 Jul-Aug;16(4):270-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: This article presents pilot data examining neural connectivity in patients with poststroke hemiparesis before and after 3 weeks of upper extremity rehabilitation in the Accelerated Skill Acquisition Program (ASAP).
  • RESULTS: Each ASAP patient showed behavioral improvement.
  • ASAP patients also showed increased influence of the affected hemisphere premotor cortex (a-PM) upon the unaffected hemisphere premotor cortex (u-PM) following therapy.

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Dec 20;26(51):13338-43 [17182784.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13848-53 [16945915.001]
  • [Cites] J Neurosci. 2007 Feb 28;27(9):2349-56 [17329432.001]
  • [Cites] Neuron. 2007 Mar 15;53(6):905-18 [17359924.001]
  • [Cites] Nature. 2007 May 3;447(7140):83-6 [17476267.001]
  • [Cites] Schizophr Bull. 2007 Jul;33(4):1004-12 [17556752.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13170-5 [17670949.001]
  • [Cites] Nat Rev Neurosci. 2007 Sep;8(9):700-11 [17704812.001]
  • [Cites] Biol Psychiatry. 2007 Sep 1;62(5):429-37 [17210143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15531-6 [17878310.001]
  • [Cites] Neuroimage. 2007 Dec;38(4):720-9 [17904390.001]
  • [Cites] Neuroimage. 2002 Aug;16(4):985-92 [12202086.001]
  • [Cites] Neuroimage. 2008 Jul 15;41(4):1382-94 [18486490.001]
  • [Cites] Int J Stroke. 2007 Feb;2(1):7-16 [18705982.001]
  • [Cites] Neuroimage. 2009 Apr 15;45(3):778-87 [19162206.001]
  • [Cites] Brain Res. 2008 Nov 6;1239:141-51 [18789314.001]
  • [Cites] Ann N Y Acad Sci. 2008 Mar;1124:1-38 [18400922.001]
  • [Cites] Neurorehabil Neural Repair. 2000;14(3):213-21 [11272478.001]
  • [Cites] Stroke. 2001 Jul;32(7):1635-9 [11441212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):253-8 [12506194.001]
  • [Cites] Hum Brain Mapp. 2003 Mar;18(3):222-32 [12599281.001]
  • [Cites] Neuroreport. 2003 Jul 18;14(10):1329-32 [12876467.001]
  • [Cites] Neuroimage. 2003 Aug;19(4):1463-76 [12948703.001]
  • [Cites] Brain. 2003 Nov;126(Pt 11):2476-96 [12937084.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 Jan;4(1):42-6 [14683627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42 [15070770.001]
  • [Cites] Arch Phys Med Rehabil. 2004 Apr;85(4):620-8 [15083439.001]
  • [Cites] Cereb Cortex. 2004 Nov;14(11):1246-55 [15166100.001]
  • [Cites] Scand J Rehabil Med. 1975;7(1):13-31 [1135616.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] J Cereb Blood Flow Metab. 1991 Mar;11(2):A121-35 [1997480.001]
  • [Cites] Exp Brain Res. 1991;84(2):393-402 [2065746.001]
  • [Cites] Brain Res. 1991 May 3;547(2):295-302 [1884204.001]
  • [Cites] J Neurosci. 1992 Jul;12(7):2542-8 [1613546.001]
  • [Cites] J Neurosci. 1994 Jun;14(6):3775-90 [8207487.001]
  • [Cites] Magn Reson Med. 1995 Oct;34(4):537-41 [8524021.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Aug;77(8):811-5 [8702377.001]
  • [Cites] Brain. 1997 Jan;120 ( Pt 1):141-57 [9055804.001]
  • [Cites] Neuroimage. 1996 Jun;3(3 Pt 1):143-57 [9345485.001]
  • [Cites] Cereb Cortex. 1997 Dec;7(8):768-78 [9408041.001]
  • [Cites] NMR Biomed. 1997 Jun-Aug;10(4-5):165-70 [9430343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):803-10 [9448244.001]
  • [Cites] Brain. 1998 Feb;121 ( Pt 2):253-64 [9549504.001]
  • [Cites] Hum Brain Mapp. 1998;6(3):160-88 [9673671.001]
  • [Cites] Neuroimage. 1998 Jul;8(1):50-61 [9698575.001]
  • [Cites] Science. 1999 Mar 5;283(5407):1538-41 [10066177.001]
  • [Cites] Neuroimage. 1999 May;9(5):534-44 [10329293.001]
  • [Cites] Stroke. 1999 Oct;30(10):2131-40 [10512918.001]
  • [Cites] Md State Med J. 1965 Feb;14:61-5 [14258950.001]
  • [Cites] Med Care. 2004 Dec;42(12):1194-201 [15550799.001]
  • [Cites] Hum Brain Mapp. 2005 Jan;24(1):59-68 [15382248.001]
  • [Cites] Stroke. 2005 Mar;36(3):635-8 [15677576.001]
  • [Cites] Neuroimage. 2005 Apr 1;25(2):462-70 [15784425.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8 [15976020.001]
  • [Cites] Stroke. 2005 Sep;36(9):2049-56 [16120847.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):10046-51 [16788060.001]
  • [Cites] Circulation. 2007 Feb 6;115(5):e69-171 [17194875.001]
  • (PMID = 19740732.001).
  • [ISSN] 1074-9357
  • [Journal-full-title] Topics in stroke rehabilitation
  • [ISO-abbreviation] Top Stroke Rehabil
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / U01 NS056256; United States / NEI NIH HHS / EY / K24EY017332; United States / NEI NIH HHS / EY / K24 EY017332; United States / NIBIB NIH HHS / EB / R01 EB002009; United States / VA / VA / VA B4657P; United States / NINDS NIH HHS / NS / 1U01NS056256; United States / NIBIB NIH HHS / EB / R01EB002009
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS437427; NLM/ PMC3595191
  •  go-up   go-down


82. Schiaffino E: The natural history: how has prostate cancer trend modified? Arch Ital Urol Androl; 2005 Jun;77(3):167-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history: how has prostate cancer trend modified?
  • The patients' number submitted to prostate fine-needle biopsy has constantly increased in the last years, posing technical and diagnostic problems to the pathologist.
  • In other cases, when only a few atypical glands are present, a very cautious behaviour is the rule.
  • The acronym "ASAP" (atypical small acinar proliferation) has been suggested in such cases.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372513.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Yanke BV, Salzhauer EW, Colon I: Is race a positive predictor of cancer on repeat prostate biopsy? J Urol; 2006 Sep;176(3):1114-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is race a positive predictor of cancer on repeat prostate biopsy?
  • PURPOSE: High grade intraepithelial neoplasia and atypical small acinar proliferation increase the probability of cancer on a subsequent prostate biopsy.
  • We investigated whether race is prognostic for detecting cancer in patients undergoing repeat prostate biopsies.
  • MATERIALS AND METHODS: At a single institution 416 men underwent 2 or more prostate biopsies from January 1993 through June 2003 for a total of 1,023 biopsies.
  • We retrospectively examined multiple factors, including patient age, race, total number of biopsy cores total number of previously negative biopsy cores, prostate specific antigen, prostate specific antigen slope, digital rectal examination and family history of prostate cancer.
  • Previous high grade intraepithelial neoplasia, atypical small acinar proliferation and Gleason score in positive biopsies were recorded from the histopathology review.
  • The Cox proportional hazards model was used for multivariate analysis.
  • When clinical and pathological variables were compared between the racial groups, black men had significantly higher prostate specific antigen (p = 0.02).
  • There was no statistically significant difference in patient age, total number of cores, number of previous negative cores, prostate specific antigen slope, abnormal digital rectal examination, family history, or previous high grade intraepithelial neoplasia or atypical small acinar proliferation.
  • Multivariate analysis showed that race approached but did not achieve statistical significance as a predictor of prostate cancer on repeat biopsy (p = 0.09).
  • Previous high grade intraepithelial neoplasia (p = 0.0025), previous atypical small acinar proliferation (p = 0.0049), digital rectal examination (p = 0.0076) and prostate specific antigen slope (p = 0.0005) were independent predictors of prostate cancer on repeat biopsy.
  • Of patients with previous atypical small acinar proliferation black men had a significantly higher rate of cancer detection on repeat biopsy.
  • CONCLUSIONS: Previous high grade intraepithelial neoplasia, atypical small acinar proliferation, digital rectal examination and prostate specific antigen slope were independent predictors of prostate cancer on repeat biopsy.
  • [MeSH-major] Biopsy, Needle / statistics & numerical data. Prostatic Neoplasms / ethnology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890704.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M: Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy. Clinics (Sao Paulo); 2008 Jun;63(3):339-42
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy.
  • INTRODUCTION: Sextant prostate biopsy remains the standard technique for the detection of prostate cancer.
  • It is well known that after a diagnosis of small acinar proliferation (ASAP) or high grade prostate intraepithelial neoplasia (HGPIN), the possibility of finding cancer is approximately 40% and 30%, respectively.
  • OBJECTIVE: We aim to analyze follow-up biopsies on patients who initially received a benign diagnosis after exclusion of HGPIN and ASAP.
  • METHODS: From July 2000 to December 2003, 1177 patients were submitted to sextant extended prostate biopsy in our hospital.
  • HGPIN and ASAP were excluded from our study.
  • CONCLUSION: Our data indicate that in extended prostate biopsy, the first biopsy detects more cancer, and the first, second, and third rebiopsies after an initial benign diagnosis succeed in finding cancer in 7.9% (6/55), 5.9% (1/15) and 20% (1/4) of patients, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatectomy. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2000 Apr;55(4):457-60 [10736483.001]
  • [Cites] J Urol. 2000 Jan;163(1):158-62 [10604336.001]
  • [Cites] J Urol. 2001 Nov;166(5):1679-83 [11586201.001]
  • [Cites] J Urol. 2002 Jun;167(6):2435-9 [11992052.001]
  • [Cites] Urology. 2002 Nov;60(5):836-40 [12429311.001]
  • [Cites] Urol Oncol. 2003 Mar-Apr;21(2):135-40 [12856642.001]
  • [Cites] J Urol. 2004 May;171(5):1850-4 [15076292.001]
  • [Cites] Urology. 2004 May;63(5):892-7; discussion 897-9 [15134973.001]
  • [Cites] Int J Biol Markers. 2004 Apr-Jun;19(2):89-92 [15255539.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):260-6 [15368469.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):1000-3 [7853548.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1822-4 [15540729.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Int Braz J Urol. 2005 Mar-Apr;31(2):131-6 [15877832.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Clinics (Sao Paulo). 2006 Dec;61(6):545-50 [17187091.001]
  • [Cites] Urology. 2000 Apr;55(4):553-9 [10736500.001]
  • (PMID = 18568243.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2664245
  •  go-up   go-down


85. Wong WW, Camp MC, Camp JS, Gupta SC: The quality of Internet advertising in aesthetic surgery: an in-depth analysis. Aesthet Surg J; 2010 Sep;30(5):735-43
MedlinePlus Health Information. consumer health - Evaluating Health Information.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The quality of Internet advertising in aesthetic surgery: an in-depth analysis.
  • BACKGROUND: The aesthetic market is a growing business, as evidenced by the American Society for Aesthetic Plastic Surgery (ASAPS) reporting an increase of 147% in the number of cosmetic procedures performed by members since 1997.
  • Using the ASAPS/American Society of Aesthetic Plastic Surgeons (ASPS) and American Medical Association Codes of Ethics as guidelines, scores were assigned to each Web site and evaluated with the provider's board certification.
  • A geographical analysis determined whether the presence of high numbers of competitors had an impact on the adherence to ethical guidelines for advertising.
  • CONCLUSIONS: Although plastic surgeons demonstrate greater overall compliance with the ASAPS/ASPS Advertising Code of Ethics, they can continue to improve.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aesthet Surg J. 2010 Sep;30(5):744 [20884906.001]
  • (PMID = 20884905.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Chung WC, Fan PL, Chiu HC, Yang CY, Huang KL, Tzeng DS: Operating room cost for coronary artery bypass graft procedures: does experience or severity of illness matter? J Eval Clin Pract; 2010 Dec;16(6):1063-70
MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on patient demographics, length of stay (LOS) and the American Society of Anesthesiologists Physical Status (ASAPS) score were extracted from the patient records.
  • Patient age and ASAPS score, hospital, and surgical volume were associated with LOS.
  • The LOS and the operation time may be the mediators of the relationship between the ASAPS score and cost, and may moderate the association of volume with cost.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20630000.001).
  • [ISSN] 1365-2753
  • [Journal-full-title] Journal of evaluation in clinical practice
  • [ISO-abbreviation] J Eval Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Cavalcanti Fde B, Alves VA, Pereira J, Kanamura CT, Wakamatsu A, Saldanha LB: Proliferative lesions of prostate: a multivariate approach to differential diagnosis. Pathol Oncol Res; 2005;11(2):103-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative lesions of prostate: a multivariate approach to differential diagnosis.
  • Prostatic needle biopsies from 142 patients were studied: 61 cases were "benign", 19 atypical small acinar proliferation, 31 high-grade prostatic intraepithelial neoplasia, and 31 adenocarcinoma.
  • Using univariate analysis of 46 previously described morphological features, 16 variables were selected, which were followed by multivariate discriminant analysis.
  • Multivariate analysis selected a small panel of histological features as those most helpful in the differential diagnosis of proliferative lesions in prostate biopsies.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Acinar Cell / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Cell Proliferation. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):925-31 [10435562.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3663-7 [2410099.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6 [1696762.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):230-2 [12610105.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):260-4 [7510946.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Am J Clin Pathol. 1983 Dec;80(6):850-4 [6195916.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):147-52 [9989840.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):1068-76 [7544958.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):821-31 [8037296.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] J Clin Pathol. 1997 Sep;50(9):775-82 [9389981.001]
  • [Cites] Virchows Arch. 1998 Nov;433(5):397-405 [9849853.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] AMA Arch Pathol. 1953 Feb;55(2):131-41 [13007281.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1073-7 [9737239.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):242-8 [1372878.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Urology. 1995 Jun;45(6):981-6 [7539563.001]
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):557-66 [12494901.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):219-23 [9024071.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23 (10 ):1173-83 [10524518.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):932-6 [10435563.001]
  • [Cites] Rev Invest Clin. 1997 Jan-Feb;49(1):37-40 [9114721.001]
  • [Cites] Histopathology. 1996 Jul;29(1):11-9 [8818689.001]
  • [Cites] Am J Pathol. 1987 Feb;126(2):384-95 [2435158.001]
  • (PMID = 15999155.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


88. Beer KR: Nasal reconstruction using 20 mg/ml cross-linked hyaluronic acid. J Drugs Dermatol; 2006 May;5(5):465-6
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to American Society for Aesthetic Plastic Surgery (ASAPS), 200,924 people had rhinoplasties in 2005.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703786.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


89. Hendriks J, Riesle J, Vanblitterswijk CA: Effect of stratified culture compared to confluent culture in monolayer on proliferation and differentiation of human articular chondrocytes. Tissue Eng; 2006 Sep;12(9):2397-405

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of stratified culture compared to confluent culture in monolayer on proliferation and differentiation of human articular chondrocytes.
  • With conventional tissue culture of cells, it is generally assumed that when the available 2D substrate is fully occupied, growth ceases or is greatly reduced.However, in nature wound repair mostly involves proliferation of cells that are attracted to the defect site in a 3D environment.Hence, proliferation continues in 3D until the defect site is filled with cells contributing to repair tissue.
  • Additionally, we studied the influence of growth factors on proliferation during stratified culture and differentiation thereafter.
  • Culture medium was based on DMEM with 10% serum and either supplemented with high concentrations of nonessential amino acids (NEAA) and ascorbic acid (AsAP), or instead with basic fibroblastic growth factor (bFGF), platelet-derived growth factor (PDBF-BB), and/or transforming growth factor beta1 (TGF-beta).
  • Furthermore, during stratified culture the number of cells increased further in the presence of bFGF, PDBF-BB, and TGFbeta1 or high concentrations of NEAA and AsAP.
  • During stratified culture in the presence of either bFGF and PDGF or high concentrations of NEAA and AsAP, exponential growth continued for up to 7 days.
  • Finally, cells maintained their differentiation capacity when cultured stratified with or without growth factors (bFGF, TGF-beta, and PDGF), but not when cultured with high levels of AsAP and NEAA.
  • [MeSH-major] Cartilage, Articular / physiology. Cell Differentiation / physiology. Cell Proliferation. Chondrocytes / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995774.001).
  • [ISSN] 1076-3279
  • [Journal-full-title] Tissue engineering
  • [ISO-abbreviation] Tissue Eng.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances
  •  go-up   go-down


90. Lum PS, Mulroy S, Amdur RL, Requejo P, Prilutsky BI, Dromerick AW: Gains in upper extremity function after stroke via recovery or compensation: Potential differential effects on amount of real-world limb use. Top Stroke Rehabil; 2009 Jul-Aug;16(4):237-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, amount of arm use may depend critically on the location, extent, and type of functional gains, which can be quantified with comprehensive kinematic and EMG analysis of ADL performance.
  • A new treatment approach called Accelerated Skill Acquisition Program (ASAP) focuses on impairment reduction coupled with repetitive, task-specific training of the paretic arm during ADLs.
  • We present pilot data that show recovery in subjects who received the ASAP, while a usual care control subject showed increased use of compensation over the same period.
  • Finally, we discuss the advantages of data reduction methods such as principal components analysis, confirmatory factor analysis, and structural equation modeling, which can potentially distill large kinematic and EMG data sets into the key latent variables that predict amount of real-world use.

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740730.001).
  • [ISSN] 1074-9357
  • [Journal-full-title] Topics in stroke rehabilitation
  • [ISO-abbreviation] Top Stroke Rehabil
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Singh KK, Erkelenz S, Rattay S, Dehof AK, Hildebrandt A, Schulze-Osthoff K, Schaal H, Schwerk C: Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold. RNA; 2010 Dec;16(12):2442-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNPS1, Acinus, and SAP18 form the apoptosis- and splicing-associated protein (ASAP) complex, which is also part of the exon junction complex.
  • Here we have investigated splicing regulatory activities of the ASAP components.
  • Detailed mutational analysis and three-dimensional modeling data revealed that the ubiquitin-like fold of SAP18 was required for efficient splicing regulatory activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] RNA. 2000 Sep;6(9):1197-211 [10999598.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2549-58 [18250153.001]
  • [Cites] RNA. 2001 Mar;7(3):421-34 [11333022.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):236-43 [12110900.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):182-5 [12226669.001]
  • [Cites] Annu Rev Genet. 2002;36:333-60 [12429696.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2981-90 [12665594.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):5-14 [12887888.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):605-12 [12923522.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):1174-87 [14729963.001]
  • [Cites] J Virol. 2004 Jun;78(12):6517-26 [15163745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8551-6 [15161980.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2004;78:37-88 [15210328.001]
  • [Cites] Mol Biol Cell. 2004 Aug;15(8):3876-90 [15169873.001]
  • [Cites] Mol Cell Biol. 1986 Sep;6(9):3173-9 [3023965.001]
  • [Cites] Biochemistry. 1987 Dec 15;26(25):8221-7 [3327519.001]
  • [Cites] EMBO J. 1993 Feb;12(2):595-600 [8440248.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5679-88 [7988565.001]
  • [Cites] Genes Dev. 1996 Jul 1;10(13):1569-79 [8682289.001]
  • [Cites] Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit 5.6 [18428767.001]
  • [Cites] Nat Struct Mol Biol. 2008 May;15(5):444-51 [18425143.001]
  • [Cites] Genes Dev. 2010 Jun 1;24(11):1073-4 [20516191.001]
  • [Cites] J Virol. 1997 Apr;71(4):2757-64 [9060629.001]
  • [Cites] Cell. 1997 May 2;89(3):357-64 [9150135.001]
  • [Cites] Nucleic Acids Res. 1998 Mar 1;26(5):1345-51 [9469847.001]
  • [Cites] J Cell Sci. 1998 Jun;111 ( Pt 11):1495-506 [9580558.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4560-70 [10449421.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):168-73 [10490026.001]
  • [Cites] Curr Biol. 2004 Dec 29;14(24):2283-8 [15620657.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1446-57 [15684395.001]
  • [Cites] Trends Biochem Sci. 2005 Mar;30(3):115-8 [15752982.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22641-50 [15837790.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):1-13 [15989960.001]
  • [Cites] EMBO J. 2005 Oct 19;24(20):3543-54 [16177823.001]
  • [Cites] RNA. 2005 Dec;11(12):1869-83 [16314458.001]
  • [Cites] J Mol Biol. 2006 Jan 27;355(4):821-44 [16310215.001]
  • [Cites] RNA. 2006 Feb;12(2):292-302 [16428608.001]
  • [Cites] Bioinformatics. 2006 Feb 1;22(3):365-6 [16332707.001]
  • [Cites] BMC Struct Biol. 2006;6:1 [16396680.001]
  • [Cites] J Comput Aided Mol Des. 2005 Nov;19(11):791-800 [16470421.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12475-84 [16537548.001]
  • [Cites] Genes Dev. 2006 Jul 1;20(13):1755-65 [16766678.001]
  • [Cites] Biochemistry. 2006 Oct 3;45(39):11974-82 [17002296.001]
  • [Cites] Protein Sci. 2006 Nov;15(11):2507-24 [17075131.001]
  • [Cites] Biochim Biophys Acta. 2008 Feb;1780(2):214-25 [18022399.001]
  • [Cites] Nucleic Acids Res. 2008 Mar;36(5):1450-63 [18203748.001]
  • [Cites] Bioinformatics. 2000 Sep;16(9):815-24 [11108704.001]
  • (PMID = 20966198.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Multiprotein Complexes; 0 / RNPS1 protein, human; 0 / Ribonucleoproteins; 0 / SAP18 protein, human; 0 / Ubiquitin
  • [Other-IDs] NLM/ PMC2995405
  •  go-up   go-down


92. Groseth A, Wolff S, Strecker T, Hoenen T, Becker S: Efficient budding of the tacaribe virus matrix protein z requires the nucleoprotein. J Virol; 2010 Apr;84(7):3603-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was recently demonstrated that while TCRV Z is still capable of functioning as a matrix protein to induce the formation of VLPs, neither its ASAP motif, which replaces a canonical PT/SAP motif in related viruses, nor its YxxL motif is involved in budding, leading to the suggestion that TCRV uses a novel budding mechanism.
  • While this budding activity is independent of the ASAP or YxxL motif, it is significantly enhanced by coexpression with the nucleoprotein (NP), an effect not seen with JUNV Z.
  • Interestingly, both the ASAP and YxxL motifs of Z appear to be critical for the recruitment of NP into VLPs, as well as for the enhancement of TCRV Z-mediated budding.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Mar;79(6):3822-30 [15731275.001]
  • [Cites] J Virol. 2009 Dec;83(23):12651-5 [19759156.001]
  • [Cites] J Virol. 2006 Apr;80(8):4191-5 [16571837.001]
  • [Cites] J Virol. 2006 Jun;80(11):5189-98 [16698999.001]
  • [Cites] Virology. 2007 Jul 20;364(1):178-83 [17382366.001]
  • [Cites] J Virol. 2007 Sep;81(17):9451-60 [17581989.001]
  • [Cites] J Virol. 2000 Apr;74(7):3293-300 [10708446.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2000 Aug 11;49(31):709-11 [10958585.001]
  • [Cites] JAMA. 2000 Sep 13;284(10):1237-8 [11001678.001]
  • [Cites] Cell. 2001 Oct 5;107(1):55-65 [11595185.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12701-5 [11606739.001]
  • [Cites] J Virol. 2001 Dec;75(24):12241-51 [11711615.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):667-72 [11792829.001]
  • [Cites] J Virol. 2002 Apr;76(8):3952-64 [11907235.001]
  • [Cites] J Virol. 2002 May;76(10):4679-87 [11967285.001]
  • [Cites] J Virol. 2003 Mar;77(5):2866-72 [12584310.001]
  • [Cites] J Virol. 2003 Mar;77(6):3882-7 [12610166.001]
  • [Cites] Antiviral Res. 2003 Jan;57(1-2):89-100 [12615305.001]
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):203-6 [12633879.001]
  • [Cites] J Virol. 2003 Oct;77(19):10383-93 [12970423.001]
  • [Cites] J Virol. 2003 Oct;77(19):10700-5 [12970458.001]
  • [Cites] Virology. 2003 Sep 15;314(1):168-78 [14517070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12978-83 [14563923.001]
  • [Cites] EMBO Rep. 2003 Nov;4(11):1084-8 [14555961.001]
  • [Cites] Virus Res. 2004 Mar 15;100(2):249-55 [15019244.001]
  • [Cites] J Virol. 2004 Jul;78(14):7344-51 [15220407.001]
  • [Cites] J Virol. 2004 Oct;78(19):10783-92 [15367645.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(4):339-90 [15487592.001]
  • [Cites] J Gen Virol. 1983 Apr;64 (Pt 4):833-42 [6682139.001]
  • [Cites] Gene. 1991 Dec 15;108(2):193-9 [1660837.001]
  • [Cites] J Virol. 1993 Feb;67(2):807-12 [8419647.001]
  • [Cites] J Virol. 1998 Jan;72(1):758-66 [9420283.001]
  • [Cites] J Virol. 2004 Dec;78(24):13793-803 [15564487.001]
  • [Cites] J Virol. 2005 Mar;79(5):2988-97 [15709019.001]
  • [Cites] Virology. 2008 Mar 15;372(2):221-32 [18063004.001]
  • [Cites] PLoS Pathog. 2008 Apr;4(4):e1000047 [18421377.001]
  • [Cites] Curr Opin Microbiol. 2008 Aug;11(4):362-8 [18602020.001]
  • [Cites] J Virol. 2008 Nov;82(22):11454-60 [18799569.001]
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000358 [19343214.001]
  • [Cites] J Virol. 2009 Jun;83(11):5606-14 [19321606.001]
  • [Cites] PLoS Pathog. 2009 May;5(5):e1000455 [19478873.001]
  • [Cites] J Virol. 2009 Jul;83(14):7029-39 [19420075.001]
  • [Cites] J Virol. 2009 Jul;83(14):7261-72 [19439476.001]
  • [Cites] Virology. 2006 Jan 5;344(1):55-63 [16364736.001]
  • (PMID = 20106925.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Glycoproteins; 0 / Nucleoproteins; 0 / Viral Proteins; 0 / Z protein, Tacaribe virus
  • [Other-IDs] NLM/ PMC2838133
  •  go-up   go-down


93. Dong J, Dai WD, Fang TL, Lin H, Uemura T: [Osteoblastic differentiation and in vivo osteogenic activity of marrow-derived mesenchymal stem cells stimulated by Tacrolimus: experiment with rats]. Zhonghua Yi Xue Za Zhi; 2007 Jan 16;87(3):190-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some MSCs were cultured with L-ascorbic acid-2-phosphate (AsAP) and beta-glycerophosphate (beta-GP) or FK506 plus AsAP and beta-GP.
  • Multiparous beta-tricalcium phosphate (beta-TCP) ceramic cubes were dipped into 2 kinds of suspension of MSCs, treated by FK506 + AsAP + beta-GP or AsAP + beta-GP, so as to produce 48 pieces of MSCs/beta-TCP complex that were randomly divided into 2 equal groups to be cultured with AsAP + beta-GP or AsAP + beta-GP + FK506 for 4 weeks.
  • RESULTS: In vitro assays showed that the APase activity, calcium deposition, expression of osteocalcin mRNA of the FK506 + AsAP + beta-GP group at any time points were all significantly higher than those of the AsAP + beta-GP group (all P < 0.05).
  • SEM showed that since the 16th day after culture calcified nodules began to be seen in the FK506 + AsAP + beta-GP group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425851.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / RNA, Messenger; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


94. Baird RE, Trigiano RN, Windham G, Williams P, Kelley R, Abbas HK, Moulton JK, Scruggs ML: Comparison of aflatoxigenic and nonaflatoxigenic isolates of Aspergillus flavus using DNA amplification fingerprinting techniques. Mycopathologia; 2006 Feb;161(2):93-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A weak association of aflatoxigenic isolates was observed, as evidenced by their clustering in 18 of 81 trees recovered from maximum parsimony analysis of binary characters derived from arbitrary signatures from amplification profiles (ASAP) data; nonaflatoxigenic isolates exhibited a pattern of paraphyletic laddering.
  • This additional work could resolve aflatoxigenic isolates of A. flavus present on maize plants using ASAP, which would reduce labor intense costs and potentially lead to faster determination of resistant cultivars in breeding efforts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1990 Aug;172(8):4238-46 [2376561.001]
  • [Cites] Can J Microbiol. 2004 Mar;50(3):193-9 [15105886.001]
  • [Cites] Science. 1991 Jun 21;252(5013):1643-51 [2047872.001]
  • [Cites] FEMS Microbiol Lett. 1996 Dec 15;145(3):377-83 [8978092.001]
  • [Cites] Lett Appl Microbiol. 2001 Oct;33(4):291-5 [11559403.001]
  • [Cites] Phytopathology. 1999 Feb;89(2):113-7 [18944783.001]
  • [Cites] Biotechnology (N Y). 1991 Jun;9(6):553-7 [1367225.001]
  • [Cites] Fungal Genet Biol. 2000 Dec;31(3):169-79 [11273679.001]
  • [Cites] J Mol Biol. 1975 Nov 5;98(3):503-17 [1195397.001]
  • [Cites] Appl Environ Microbiol. 1991 Sep;57(9):2482-6 [1768121.001]
  • [Cites] Anal Biochem. 1991 Jul;196(1):80-3 [1716076.001]
  • [Cites] Methods Enzymol. 1987;155:335-50 [3431465.001]
  • [Cites] Curr Genet. 2001 Jul;39(5-6):346-54 [11525409.001]
  • [Cites] Mycol Res. 2003 Dec;107(Pt 12):1427-34 [15000243.001]
  • (PMID = 16463092.001).
  • [ISSN] 0301-486X
  • [Journal-full-title] Mycopathologia
  • [ISO-abbreviation] Mycopathologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / DNA, Fungal; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


95. Mansilha CR, Coelho CA, Reinas A, Moutinho A, Ferreira S, Pizarro C, Tavares A: Salmonella: the forgotten pathogen: health hazards of compliance with European bathing water legislation. Mar Pollut Bull; 2010 Jun;60(6):819-26
MedlinePlus Health Information. consumer health - Water Pollution.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attending the high prevalence of Salmonella found (23.1%) it seemed important to improve the efficiency of the conventional analytical method (ISO 6340:1995), comparing its draft with SML-VIDAS Salmonella and two new chromogenic media: AES Salmonella Agar Plate (ASAP) and Simple Method Salmonella (SMS).
  • ASAP showed the higher efficiency and can be recommended for a faster detection and presumptive identification of salmonellae in bathing waters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20152993.001).
  • [ISSN] 1879-3363
  • [Journal-full-title] Marine pollution bulletin
  • [ISO-abbreviation] Mar. Pollut. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromogenic Compounds
  •  go-up   go-down


96. Leite KR, Srougi M, Sanudo A, Dall'oglio MF, Nesrallah A, Antunes AA, Cury J, Camara-Lopes LH: The use of immunohistochemistry for diagnosis of prostate cancer. Int Braz J Urol; 2010 Sep-Oct;36(5):583-90
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry for diagnosis of prostate cancer.
  • PURPOSE: Atypical glands (ASAP) are diagnosed in 5.0% of prostate biopsies, and cancer identification in a rebiopsy is higher than 40.0%.
  • MATERIALS AND METHODS: Out of 4127 biopsies examined from 2004 to 2008, 144 (3.5%) were diagnosed with ASAP.
  • The results of surgical specimens of 27 patients treated by RP after the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was not necessary (Group 2).
  • Therefore, our results suggest that this modality should be routinely used for a borderline biopsy and ASAP cases.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Cell Proliferation. Humans. Immunohistochemistry / methods. Male. Middle Aged

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21044375.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


97. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJ: False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol; 2010 Jan;34(1):35-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.
  • Little is known about the frequency, histopathologic characteristics, and clinical consequences of false-negative prostate biopsies, that is, biopsies classified as benign but containing adenocarcinoma or atypical suspicious glands [atypical small acinar proliferations (ASAP)].
  • Objective of this study was to evaluate false-negative prostate biopsy in a prostate cancer screening setting.
  • Prostate biopsy sets of 196 participants of a screening trial, which had been reported as "benign" at initial diagnosis, followed by a diagnosis of adenocarcinoma in a subsequent screening round were reviewed by 2 urologic pathologists.
  • Adenocarcinoma was identified in 19 biopsy cores corresponding to 16 (8.2%) patients and ASAP in 24 cores, corresponding to 19 patients (9.7%).
  • All missed prostate cancers were Gleason score 6 (3+3).
  • After correction for patient selection, the overall false-negative biopsy rate was estimated to be 2.4%; 1.1% for prostate cancer; and 1.3% for ASAP.
  • Clinicopathologic features at the time of initial biopsy and of subsequent prostate cancer diagnosis did not differ between patients with a false-negative or true benign biopsy.
  • Relatively low number of atypical glands (<10 glands), intense intermingling with preexistent glands or lack of architectural disorganization were the most prominent risk factors for a false-negative diagnosis.
  • Another potential pitfall was the presence of prostate cancer variants, as 1 adenocarcinoma was of foamy gland type and 3 of pseudohyperplastic type.
  • Routine examination of at least 1 level of prostate biopsy sets at high magnification and awareness of histologic prostate cancer variants might reduce the risk of missing or misinterpreting a relevant lesion at prostate biopsy evaluation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy, Needle. Diagnostic Errors. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. False Negative Reactions. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935058.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


98. Paradela S, Martínez-Gómez W, Fernández-Jorge B, Castiñeiras I, Yebra-Pimentel T, Llinares P, Fonseca Capdevila E: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus; 2007;16(9):741-5
MedlinePlus Health Information. consumer health - Lupus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term "Acute Syndrome of Apoptotic Pan-Epidermolysis" (ASAP) designs clinical entities characterized by massive cleavage of the epidermis resulting from hyperacute epidermal basal cell apoptotic injury.
  • Although most cases of ASAP in the setting of LE are drug-induced TEN, there are reported cases of "TEN-like" LE with subacute progression, absence of systemic involvement and lack of drug ingestion.

  • Genetic Alliance. consumer health - Cutaneous Lupus Erythematosus.
  • Genetic Alliance. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lupus. 2008 Jun;17(6):605-6 [18539717.001]
  • (PMID = 17728369.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Horton NJ, Kim E, Saitz R: A cautionary note regarding count models of alcohol consumption in randomized controlled trials. BMC Med Res Methodol; 2007 Feb 15;7:9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cautionary note regarding count models of alcohol consumption in randomized controlled trials.
  • BACKGROUND: Alcohol consumption is commonly used as a primary outcome in randomized alcohol treatment studies.
  • The distribution of alcohol consumption is highly skewed, particularly in subjects with alcohol dependence.
  • We compare the Type-I error rate of these methods in a series of simulation studies of a randomized clinical trial, and apply the methods to the ASAP (Addressing the Spectrum of Alcohol Problems) trial.
  • RESULTS: Standard Poisson models provide a poor fit for alcohol consumption data from our motivating example, and did not preserve Type-I error rates for the randomized group comparison when the true distribution was over-dispersed Poisson.
  • For the ASAP trial, where the distribution of alcohol consumption featured extensive over-dispersion, there was little indication of significant randomization group differences, except when the standard Poisson model was fit.
  • CONCLUSION: As with any analysis, it is important to choose appropriate statistical models.
  • To appropriately model alcohol consumption, more flexible count models should be routinely employed.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Ann Intern Med. 2007 Feb 6;146(3):167-76 [17283347.001]
  • [Cites] J Gen Intern Med. 2006 Apr;21(4):381-5 [16686818.001]
  • [Cites] Psychol Bull. 1995 Nov;118(3):392-404 [7501743.001]
  • (PMID = 17302984.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA012617; United States / NIAAA NIH HHS / AA / R01-AA12617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1810542
  •  go-up   go-down


100. Montironi R, Vela Navarrete R, Lopez-Beltran A, Mazzucchelli R, Mikuz G, Bono AV: Histopathology reporting of prostate needle biopsies. 2005 update. Virchows Arch; 2006 Jul;449(1):1-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology reporting of prostate needle biopsies. 2005 update.
  • This report reviews the diagnostic and prognostic importance of the pathologic findings in prostate needle biopsies.
  • The morphological findings of the needle biopsy may be placed into one of the following five categories: prostate cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, inflammation, and benign prostatic tissue.
  • While the prime goal of the biopsy is to diagnose prostatic adenocarcinoma, once carcinoma is detected, further descriptive information regarding the type, amount of cancer, and grade forms the cornerstone for contemporary management of the patient and for assessment of the potential for local cure and the risk for distant metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / trends. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2000 Apr;37(4):404-12 [10765070.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] Arch Pathol Lab Med. 1995 May;119(5):444-7 [7748073.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):887-91 [7543443.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):82-93 [16019760.001]
  • [Cites] BJU Int. 2006 Mar;97(3):492-7 [16469014.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] J Urol. 2002 Jun;167(6):2440-2 [11992053.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):516-20 [11792909.001]
  • [Cites] Hum Pathol. 2001 Aug;32(8):828-33 [11521227.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1203-8 [14501725.001]
  • [Cites] Cytometry. 1993;14(5):497-500 [8354122.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):307-15 [14739905.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Urology. 2004 Jun;63(6):1105-10 [15183961.001]
  • [Cites] Urol Clin North Am. 1993 Nov;20(4):589-95 [8273267.001]
  • [Cites] BJU Int. 2005 Jun;95(8):1146-52 [15877724.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):442-50 [12219787.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):41-5 [8841465.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Pathology. 2003 Dec;35(6):472-9 [14660096.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):424-5 [9563798.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):20-33 [16019757.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1884-93 [12673714.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2344-50 [14635068.001]
  • [Cites] J Urol. 2004 Mar;171(3):1093-7 [14767278.001]
  • [Cites] Cancer. 1991 Jun 15;67(12 ):2949-58 [1710531.001]
  • [Cites] Urology. 2003 Mar;61(3):589-95 [12639653.001]
  • [Cites] J Urol. 2004 Mar;171(3):1122-7 [14767284.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):752-7 [2386903.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):266-8 [8135180.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1186-91 [11106075.001]
  • [Cites] J Urol. 2002 Nov;168(5):1994-9 [12394693.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Eur Urol. 1993;23 Suppl 2:64-76 [7685705.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 [14697416.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] BMJ. 2001 Feb 17;322(7283):378-9 [11179143.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Urology. 2005 Mar;65(3):538-42 [15780372.001]
  • [Cites] J Urol. 2003 Jun;169(6):2136-41 [12771735.001]
  • [Cites] Urol Int. 2003;70(4):297-302 [12740495.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S31-7 [7524305.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):8-19 [16019756.001]
  • [Cites] Urology. 1999 Apr;53(4):752-6 [10197851.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1511-21 [9137077.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1050-4 [7487406.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):177-81 [15245810.001]
  • [Cites] J Urol. 2003 Nov;170(5):1792-7 [14532778.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):477-8 [10757394.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Pathol Res Pract. 1993 Jun;189(5):542-8 [7690954.001]
  • [Cites] Urology. 1996 Jul;48(1):47-57 [8693651.001]
  • [Cites] Arch Ital Urol Androl. 2005 Mar;77(1):31-6 [15906787.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Urol. 1997 Apr;157(4):1301-3 [9120926.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1087-92 [9719119.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2196-204 [11391602.001]
  • [Cites] Hum Pathol. 1993 Nov;24(11):1159-67 [8244315.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):94-110 [16019761.001]
  • [Cites] Urology. 1997 Jun;49(6):857-62 [9187691.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):223-8 [9930144.001]
  • (PMID = 16633784.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 81
  •  go-up   go-down






Advertisement